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ABSTRACT 
 
Hip osteoarthritis is a leading cause of disability in the population, and its 
burden is expected to increase as a result of its raising incidence. Hip 
osteoarthritis is associated with progressive destruction of the cartilage, and 
although a definitive characterization of the pathways implied in the process of 
cartilage injury is still not clear, the role of inflammation in hip osteoarthritis 
pathogenesis, progression and severity is becoming evident, due to the 
actions of pro inflammatory cytokines and proteinases in the hip, responsible 
for cartilage degradation, without rescue responses that can compensate this 
process. 
Total hip arthroplasty is a highly cost effective surgery in patients with hip 
osteoarthritis refractory to non-operative treatment. Developments in implants 
materials and production are responsible for increased survival of total hip 
arthroplasty in the long term. Nevertheless the rate of revision arthroplasty is 
expected to increase significantly in the upcoming years. Aseptic loosening is 
the main cause for failed arthroplasty and revision surgery. This process is 
caused by numerous and very small particles released from implants 
stimulating the release of pro-inflammatory and pro-osteoclastic cytokines that 
simultaneously increase the number, survival and activity of osteoclasts and 
inhibit osteoblasts. 
Neurotransmitters and peripheral nervous system have been described to be 
involved in the pathophysiology of osteoarticular diseases, namely 
inflammatory diseases. Sensory and sympathetic nerve fibers have an 
important role in chronic inflammation regulation and bone resorption, by 
influencing the pro-inflammatory and anti-inflammatory cytokines 
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concentrations and actions. However we know little regarding their actions in 
the development of hip osteoarthristis and even less in the failure of total hip 
arthroplasty. 
The main objective of this PhD Thesis was to investigate the involvement of 
the neuroimmune axis in the biological events leading to hip osteoarthritis and 
aseptic loosening. 
First, we assessed the nervous and immune system profile of patients with hip 
osteoarthritis when compared to healthy controls. We performed the first 
systematic review on neuroimmune expression in hip osteoarthritis patients 
using data from studies in humans, allowing an integrated approach of the 
changes caused by hip osteoarthritis, both at a local and systemic level. Our 
review highlights the lack of a clear analytical profile of hip osteoarthritis, both 
systemically and locally. We found deregulation in the balance of pro-
inflammatory versus anti-inflammatory cytokines. Regarding the influence of 
the neuroimmune axis in the biological events leading to hip osteoarthritis, 
only two articles were found relating neuropeptides expression to the 
pathogenesis of hip osteoarthritis, which is representative of the lack of 
available information in this area. 
Second, we characterized the immune and innervation profiles of hip aseptic 
loosening patients when compared with patients with hip osteoarthritis. This 
was the first study performing this analysis in the hip of human patients, and 
brought a new insight into the role of the neuroimmune axis in hip 
osteoarthritis and aseptic loosening patients. Our results demonstrate 
differences both in the immune response and local innervation of hip 
osteoarthritis when compared to aseptic loosening patients. Both present 
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sensory innervation, with different distribution between both groups, but there 
is an absence of sympathetic nerve fibers in aseptic loosening tissues when 
compared to osteoarthritis. This is a distinct feature in the innervation profile in 
these patients and the first time it was described. 
Finally, we characterized the impact of aseptic loosening in the activity of the 
sympathetic nervous system. Following the results described in our previous 
work, we evaluated the systemic and local profile of neuroimmune molecules 
involved in the interplay between the sympathetic nervous system and the 
periprosthetic inflammation in hip aseptic loosening. We confirmed that the 
usual effectors for the sympathetic anti-inflammatory action were absent in 
macrophages in aseptic loosening patients, but present in the osteoarthritis 
group. These findings are in favor of a local reduction of the anti-inflammatory 
effects performed by the sympathetic system, and the perpetuation of a pro-
inflammatory environment in aseptic loosening patients. Systemically we 
found no impact of these changes in the Hypothalamus-Pituitary-Adrenal axis 
activity, which leads us to consider that in humans these pathological 
responses occurring at the hip are mostly confined to the joint. 
Overall, under the scope of this thesis, we described a new pattern of 
innervation in aseptic loosening, characterized by the absence of sympathetic 
activity. This impairment occurs locally at the hip, affecting both adrenergic 
and Neuropeptide Y-ergic signaling, without systemic translation. This finding 
highlights the local sympathetic signaling as a putative target to mitigate the 
inflammatory response to debris release and consequently extending the 
lifespan of orthopedic implants.  
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RESUMO 
 
A osteoartrite da anca é uma das causas mais importantes de incapacidade 
na população, sendo expectável um aumento do seu impacto 
socioeconómico, resultado da sua crescente incidência. A osteoartrite da 
anca está associada a uma destruição progressiva da cartilagem, e embora 
os mecanismos implicados neste processo não estejam totalmente 
esclarecidos, o papel da inflamação na sua patogénese, progressão e 
gravidade tem-se tornado evidente, decorrente da acção de citocinas pró-
inflamatórias e proteinases na anca, responsáveis pela destruição da 
cartilagem, perante a ausência de mecanismos de compensação eficientes. 
A artroplastia total da anca é um procedimento altamente custo efectivo em 
doentes com osteoartrite da anca refractários ao tratamento conservador. 
Desenvolvimentos nos materiais e na produção de implantes têm sido 
responsáveis por um aumento na sobrevida das artroplastias totais da anca a 
longo prazo. No entanto, é expectável que as taxas de artroplastia de revisão 
da anca aumentem de forma significativa nos próximos anos. O 
descolamento asséptico é a principal causa para falência desta artroplastia e 
cirurgia de revisão. É um processo causado pelas numerosas partículas de 
pequenas dimensões, libertadas pelos implantes, que estimulam a libertação 
de citocinas pró-inflamatórias e pró-osteoclásticas, que simultaneamente 
aumentam o número, sobrevida e actividade dos osteoclastos e inibem os 
osteoblastos. 
Os neurotransmissores e o sistema nervoso periférico têm sido descritos 
como estando envolvidos na patogénese de doenças osteoarticulares, 
particularmente nas doenças inflamatórias. As fibras sensitivas e simpáticas 
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têm um papel importante na regulação da inflamação crónica e da 
reabsorção óssea, ao influenciarem a concentração e ação das citocinas pró 
e anti-inflamatórias. Contudo, o conhecimento acerca do seu papel no 
desenvolvimento da osteoartrite da anca e na falência das artroplastias totais 
da anca é ainda limitado. 
O principal objectivo desta Tese de Doutoramento foi investigar o papel do 
eixo neuroimune no desenvolvimento da osteoartrite da anca e no 
descolamento asséptico. 
Inicialmente avaliamos o perfil nervoso e imune de doentes com osteoartrite 
da anca quando comparados com controlos saudáveis. Realizámos a 
primeira revisão sistemática sobre expressão neuroimune em doentes com 
osteoartrite da anca, utilizando dados sobre estudos em humanos, permitindo 
uma abordagem integrada das alterações causadas pela osteoartrite da 
anca, tanto a nível local como sistémico. A nossa revisão enfatiza a falta de 
um perfil analítico claro da osteoartrite da anca tanto a nível sistémico como 
local. Relatamos a existência de uma desregulação no balanço de citocinas 
pró versus anti-inflamatórias. Relativamente ao papel do eixo neuroimune no 
desenvolvimento de osteoartrite da anca, apenas dois artigos foram 
encontrados, evidenciando a escassez de informação disponível nesta área. 
De seguida caracterizámos o perfil imune e de inervação em doentes com 
descolamento asséptico da anca quando comparados com doentes com 
osteoartrite da anca. Este é o primeiro estudo disponível que realiza esta 
análise em doentes humanos, revelando uma nova informação sobre o papel 
do sistema neuroimune na osteoartrite da anca e no descolamento asséptico. 
Os nossos resultados demonstram diferenças na resposta imune e inervação 
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local de doentes com osteoartrite da anca quando comparados com 
descolamento asséptico. Ambos apresentam evidência de inervação 
sensitiva, mas com distribuição diferente entre os grupos, verificando-se uma 
ausência de fibras simpáticas no grupo com descolamento asséptico quando 
comparado com osteoartrite da anca. Esta é uma característica distinta da 
inervação entre estes grupos, tendo sido a primeira vez que foi descrita. 
Por último, caracterizámos o impacto do descolamento asséptico na 
actividade do sistema nervoso simpático. Seguindo os resultados descritos 
no nosso trabalho anterior, avaliámos o perfil sistémico e local das moléculas 
neuroimunes envolvidas na relação entre sistema nervoso simpático e 
inflamação periprotésica no descolamento aséptico da anca. 
Confirmámos que os efetores habituais da ação anti-inflamatória do sistema 
simpático estavam ausentes nos macrófagos de doentes com descolamento 
asséptico, mas presentes nos do grupo de osteoartrite da anca. Estes 
achados são a favor de uma provável redução dos efeitos anti-inflamatórios 
locais por parte do sistema nervoso simpático, e de uma perpetuação do 
ambiente pró-inflamatório em doentes com descolamento asséptico. 
Sistemicamente não encontrámos qualquer impacto destas alterações ao 
nível da actividade do eixo hipotálamo-hipófise-suprarrenal, o que nos leva a 
considerar que no humano estas alterações patológicas na anca estão 
essencialmente confinadas à articulação per se. 
Em resumo, nesta tese, descrevemos um novo padrão de inervação no 
descolamento asséptico, que se caracteriza pela ausência de actividade 
simpática. Esta alteração verifica-se ao nível da anca, afectando o sistema 
adrenérgico e neuropéptido Y-érgico, sem tradução sistémica. Estes 
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resultados realçam a possibilidade do sistema nervoso simpático local ser 
usado como um possível alvo terapêutico para minimizar a resposta 
inflamatória aos resíduos libertados, e consequentemente, aumentar a 
sobrevida dos implantes ortopédicos.  
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Hip osteoarthritis (HOA) is a leading cause of disability in the elderly, with 
radiographic signs present in more than 5% of people over 65 years old (1). 
The risk of developing symptomatic HOA is more than 25% in population that 
lives up to 85 years and the risk of undergoing total hip arthroplasty (THA) is 
estimated at 10% for general population (2). This makes HOA one of the most 
common and important joint disorders. 
 
Impact of Hip Osteoarthritis 
Society burden associated with HOA is expected to increase significantly as a 
result of its raising incidence. This is related with the increase in life 
expectancy and the subsequent aging of population, together with the 
increase of diseases with impact in joint degeneration, such as obesity, as 
well as the lack of effective disease-modifying drugs active in HOA (3, 4).  
HOA is known to have a significant impact on quality of life, causing severe 
pain and disability. This is reflected in multiple reports on the increase of 
disability-adjusted life years (DALYs) and on years of life lived with disability 
(YLDs) observed from 1990 to 2010 (3). Actually, HOA is currently one of 
most worrisome diseases reported in the Global Burden Disease 2010 (3).  
HOA burden is reflected not only on the individual but also on a society level. 
It is responsible for decreased productivity, premature leave from the 
workplace, loss of autonomy, increased needs for healthcare services, 
personal assistance and institutionalization. Salmon et al estimated annual 
direct costs from 0.5 to 10.9 thousand-euros/year per patient and indirect 
costs from 0.2 to 12.3 thousand-euros/year per patient (4). The weighted 
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average annual costs were 11.1, 9.5 and 4.4 thousand-euros/year per patient 
for total, direct and indirect costs, respectively. 
 
Biological Background of Hip Osteoarthritis 
Osteoarthritis encompasses a mixed group of joint disorders that have a 
common presentation with decreased range of motion and pain. In particular, 
HOA is associated with synovial inflammation, followed by progressive 
destruction of the cartilage in a nonuniform fashion, subchondral bone 
thickening and finally formation of osteophytes (1, 2). 
For a long period HOA was considered a “wear and tear” disease. However 
the increasing evidence of synovitis in the early phases of this disease raised 
the possibility that both inflammation and the immune system could be 
involved in the development and progression of HOA (5). 
The pathogenesis of HOA is far from being clearly established (1, 6). 
Biomechanical factors have been implicated in this process. Repetitive 
stresses at the cartilage surface can cause molecular and cellular changes 
related to HOA development. Inappropriate mechanical loading to the hip joint 
leads to cartilage injury by degradation of the matrix macromolecules and 
decreased expression of proteins necessary for normal joint function, such as 
aggrecan proteoglycan and type II collagen. In response there is an increase 
in the synthesis of other proteoglycans and type I collagen, characteristic of 
immature cartilage. This shift in cartilage phenotype results in a matrix that is 
not able to preserve normal hip function (7, 8). Together these can lead to an 
increase in apoptotic cellular response and in the release of pro-inflammatory 
cytokines, as nitric oxide (2, 7, 8). However, a definitive characterization of 
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biochemical pathways and signalling molecules implied in the process that 
drive cartilage injury is still not clear (6).  
In the beginning of osteoarthritis (OA) development, cartilage reacts in an 
attempt of an early repair, with chondrocyte proliferative, increased production 
of cartilage matrix, and a simultaneous increase in catabolic cytokines and 
matrix-degrading enzymes. The lesion progresses with a reduction of the 
tensile forces in the cartilage matrix, caused by cleavage of type II collagen 
and loss of proteoglycans (9). Pro inflammatory cytokines interleukin (IL)-1 
and tumor necrosis factor (TNF)-α have a central role in this process, 
sustaining the inflammatory process and targeting chondrocytes, stimulating 
them to secret catabolic enzymes, what enhances cartilage destruction (9, 
10). Although the mechanism is yet to be found, increased levels of these 
cytokines have been found in OA synovial fluids, even in the absence of 
infiltration of macrophages and neutrophils into joint tissues (11). 
Synovitis and lymphocytic infiltration have also been reported in early-stage 
OA (2). The fibroblast- and macrophage-like synovial cells, may produce 
catabolic cytokines in response to breakdown products from the damaged 
cartilage, and are potential sources of cytokines that could induce 
chondrocytes to synthesize and secrete cartilage-degrading proteases and 
other cytokines and proinflammatory mediators (11).  
 
Role of Inflammation in Hip Osteoarthritis 
Several authors reported the presence of inflammation in synovial tissue of 
patients with HOA. This is characterized by inflammatory and immune cell 
Chapter	I	–	General	Introduction;	Aims	of	the	Thesis	
	 26	
infiltration, cytokine secretion, hyperplasia of synovial lining cells and 
activation of resident cells (5, 12). 
Macrophages in the lining layer (LL) and T cells in the sublining layer (SLL) 
are the most abundant cells. Mast cells (in the SLL and around blood 
vessels), B cells and plasma cells were also found, although in smaller 
amounts (13). Also, different cytokines associated with immune cells have 
been detected in OA synovial tissue (5, 14). These are indicative of a role 
played by inflammation in HOA pathogenesis, progression and severity. 
Cytokines have a proven physiological function in normal tissues, being 
essential at low concentrations for normal homeostasis (11). In HOA this 
balance is compromised, and cytokines are present in increased levels, with 
distorted ratios, acting on resident cells in a paracrine-autocrine fashion (11).  
As previously referred IL-1 and TNF-α play a central role in HOA 
pathophysiology. In vitro and animal model studies demonstrated that IL-1-β 
stimulates the expression of other pro-inflammatory cytokines as IL-6 and 
TNF-α (15). It also inhibits the function of extracellular matrix proteins growth 
factors. TNF-α presents similar effects to, and is synergistic with IL-1 in the 
process of cartilage destruction (16, 17). Other identified catabolic and pro-
inflammatory cytokines include IL-8, IL-17, IL-18, oncostatin-M (OSM) and 
leukemia inhibitory factor (LIF) (18).  
Inhibitory cytokines that block the action of catabolic cytokines were found in 
synovial fluid, which was interpreted as an attempt to control the catabolic 
process (11).  
These anti-inflammatory factors include IL-1 receptor antagonist (IL-1ra), 
interferon (IFN)-α, IL-4, IL-10, IL-11 and IL-13 (19). Other factors that oppose 
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this destructive cartilage process were also found in vitro, as insulin-like 
growth factor-I, transforming growth factor (TGF)-β /bone morphogenetic 
protein (BMP) family, and fibroblast growth factors (FGFs) (20). These are 
cartilage anabolic factors. Other factors as IL-6 and TGF-β may have dual 
roles (11). 
An imbalance in both proteinases and inhibitors produced by cartilage cells, 
which influence cartilage destruction was also reported. Matrix 
metalloproteinases (MMPs) are the best-known factors implied in degradation 
of proteoglycans and collagens and were found in cartilage and synovial 
samples from OA patients (21). In reaction to local increased levels of these 
active MMPs, inhibitors of metalloproteinases (TIMPs) are also increased 
(22). However, this raise is neither sufficient, nor effective, to counteract the 
high levels and actions of MMPs. 
This process creates a vicious circle, where degradation products and 
fragments of cartilage released in the joint cavity trigger local inflammatory 
response by the synthesis of catabolic cytokines, which perpetuate and 
amplify cartilage destruction (11).  
Moreover, the adaptive response, with increased expression of type II 
collagen and repair of matrix components, is limited and adult mature 
chondrocytes cannot regenerate the normal cartilage matrix architecture (11, 
16). 
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Total Hip Arthroplasty Evolution and Survival Rates  
THA is a very effective treatment for patients with refractory pain and 
significant disability. It is currently indicated in patients with HOA presenting 
with substantial discomfort and functional impairment, upon failure of 
conservative treatment. Nevertheless, the best timing for joint-replacement 
surgery is not yet established (1). 
Although the first studies showed a significant failure rate soon after the 
surgery (1% a year over a period of 10 years), posterior development in 
implants’ design, materials and fixation techniques overcame this problem, 
with modern implants presenting a long survival rate after implantation (1, 23). 
Nowadays, more than 1 million THA are performed annually. THA has been 
demonstrated to be a highly cost effective surgery in patients refractory to non 
operative treatment (2). 
THA implants consist of femoral and acetabular components that can be fixed 
in different ways. The available systems are usually modular and consist of 
independent femoral head, femoral stem, acetabular shelf and acetabular 
liner. The fixation can be achieved by the use of cement or by bony growth 
onto or into the porous implant surface (24).  
THA survival in the long term is related to the amount of debris released by 
the bearing surfaces and the longevity of component fixation (25, 26). This is 
one of the main spotlights in the designing and development of arthroplastic 
implants and their fixation, with efforts being made to improve their 
survivorship and function. These advances are responsible for the current 
98% survivorship at 10 years, and 93% survivorship at 25 years of modern 
cemented stems (25). Also for cementless femoral components similar 
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survival rates have been reported. They present comparable survival at 10 
years (95–100%), but a slightly better survival at 15 years (85–94% versus 
70–95%) (26). Although both cementless and cemented femoral implants 
present excellent long-term survival rates, the cementless implants are 
currently the first choice for the majority of surgeons (23, 24).  
The technological development of modern non-cemented stems has included 
the use of metal alloys that are more biologically inert and less stiff, and the 
use of porous coatings. A trend towards an increased modularity has also 
been seen, allowing the possibility of different head sizes and offset options 
for the same stem, as well as different bearing surfaces for the femoral head 
(24). These developments displayed a huge array of intra-operatory solutions 
with a unique stem that is both more similar in elasticity to the bone and has 
optimal bone ingrowth properties (23, 24). 
New metals have also been developed, with the emergence of highly porous 
metal alloys (trabecular metal and tantalum) that are not only more porous 
and similar to bone, but can also be manufactured in different sizes and 
shapes, increasing the available solutions for both primary and revision 
surgeries (26). In fact, their demonstrated soft tissue and bone ingrowth 
proprieties led to an increase in their use (23, 24, 27).  
Osteolysis, associated with wear debris from polyethylene, motivated the 
development of new bearing surfaces including cross-linked ultra-high-
molecular-weight polyethylene (UHMWPE) (28). This proved to be more 
resistant then the standard ones, and became the most frequently used 
bearing surface worldwide (28). 
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Other new combinations besides the metal on polyethylene have also been 
developed. 
Ceramic on ceramic or ceramic on highly cross-linked polyethylene 
articulations, became popular, as they present less friction and produce a 
small number of wear particles.  Despite the absence of longer follow-ups, 10-
year studies on ceramic on ceramic and ceramic on polyethylene 
demonstrated a significant success of these pairs (29). With the development 
of new ceramics, with diminished risk of fracture, the utilization of ceramic on 
ceramic or ceramic on highly cross-linked polyethylene is expected to be 
popularized in the upcoming years (24, 29).  
Metal-on-metal bearing surfaces also present diminished friction, with low 
wear rates and particle production. Clinical studies with intermediate follow up 
(5-10 years) in young patients have demonstrated good results, but concerns 
regarding the systemic effects of released and absorbed ions were reported, 
as their role in organ failure or carcinogenic pathways are not yet known, and 
have halted the early popularity of this option (24, 30). 
 
Revision Total Hip Arthroplasty: burden and complications 
Even with these improvements in implants survival, the rate of arthroplasty 
revision is expected to grow over the next 20 years by 137% (31, 32). 
Revision THA represents a challenge, and is associated with re-revision rates 
of 15.8% at 1 year, as described by Badarudeen et al (31). The risk of 
complication in the second procedure is significantly higher than in the first 
revision (31, 33, 34). Moreover patients that undergo revision surgery are 
progressively more complex, with increased comorbidities, increasing even 
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more the rate of adverse events (33). The mortality risk in these cases is 
rising, opposing the tendency in primary THA (33). Previous works reported 
mortality rates of 0.87%-2.6% in the first 6 weeks after the revision THA 
surgery (31, 33, 34). Other serious complications in these patients include 
infection (up to 17,3%), re-revision (15.8%), venous thromboembolic disease 
(11.1%), dislocation (5.43-14,4%), pulmonary embolism (3.24%), and death 
(2.11%) (31, 33, 34).  
The main factor for failed primary THA in both mid and long term is aseptic 
loosening, responsible for about 70% of the revisions (23, 25). Aseptic 
loosening is a low-grade inflammatory process, where a macrophage driven 
process leads to bone resorption, implant loosening and arthroplasty failure 
(35). It is usually asymptomatic for years and is preceded by periprosthetic 
osteolysis, due to progressive destruction and disappearance of the bone that 
contacts the implant (35). Rates for osteolysis were reported in 5-20%, but 
these numbers are expected to increase significantly, because nowadays we 
are doing more THA procedures overall, especially in younger patients (40% 
of patients submitted to THA are below 65 years). (32). Younger patients, with 
increased life expectancy, are more probable to experience osteolysis and 
aseptic loosening throughout their life (36).  
THA longevity is affected by several factors including gender, age and 
surgeon’s skills (36). The conditions pre dating the primary arthroplasty can 
also have an effect in the occurrence of aseptic loosening. Accordingly, male 
patients below 40 years old, and those with sequelae of congenital diseases 
are more prone to this type of failure. Also, uncemented implants might be 
less affected than cemented implants (36). 
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The ability to reduce the number of revision procedures would have a 
significant impact both in patient outcomes, and on the healthcare system. 
 
Periprosthetic Inflammation and Aseptic Loosening 
The recent improvements in THA function and durability are related to the 
utilization of cross linked UHMWPE, cobalt chromium (CoCr), and alumina 
ceramics that contribute to a positive balance between friction, lubrication and 
wear (32). 
In normal circumstances, the host reacts to all types of implanted biomaterials 
with a foreign-body response. When it comes to definitive implants this 
response is aberrant and continued, aiming to isolate the foreign material from 
the surrounding tissue, achieved by coating the tissue-material interface with 
a collagenous and avascular membrane. The initial step in this process is a 
complex inflammatory process interaction at the tissue-blood-material 
interface (37). 
The inflammation is the body’s normal protective response to any injury 
(including surgery) or foreign bodies. In this process, vascular permeability is 
increased by neuropeptides, as calcitonin gene related peptide (CGRP) and 
Substance P (SP), followed by the attraction of neutrophils and other 
polymorphonuclear leukocytes (PMN) to the injury site, and subsequent 
recruitment and activation of macrophages (38, 39). Macrophages assemble 
at the implant site and lead to further production of chemo-attractive signalling 
molecules such as platelet-derived growth factor (PDGF), TNF-α, IL-6, 
granulocyte-colony stimulating factor (G-CSF), and granulocyte macrophage 
colony stimulating factor (GM-CSF), that perpetuate this process (40). In the 
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final stage of this response, a chronic inflammation status ensues, 
characterized by infiltration of macrophages and fibroblasts, as well as 
neovascularization within the new-formed tissue (granulation tissue), that is a 
precursor for the future fibrous capsule (32, 41). This is a protective and 
physiological response from the host to a foreign body, as is the case with an 
arthroplasty. It is completely different from the response to wear particles 
released by different biomaterials. 
Wear debris and particles from THA implants released due to fatigue, 
adhesion and excessive abrasion in the articulating interfaces of the implants 
components, can initiate important immunological reactions, that eventually 
cause implant failure (32). 
William Harris was one of the first to describe this phenomena and called it 
“particle disease”, highlighting the importance of the particles generated by 
the implants in the development of a deleterious host response (42). The 
amount of bone destruction and resorption is, in part, dependent on the origin, 
size and amount of the prosthetic particles that reciprocally condition the 
severity and depth of the deregulated osteolytic response (41, 42). In particle 
disease, numerous and very small particles (less than micrometers in size) 
released from the implants cause periprosthetic cells to produce pro-
inflammatory/pro-osteoclastic cytokines that simultaneously increase the 
number, survival and activity of osteoclasts and inhibit osteoblasts (41). 
The joint fluid produced by the synovial-like membrane composed of 
macrophages and fibroblasts, facilitates the spreading of particles across the 
joint. The fluid not only washes the particles from the articulating area, but 
also transports the signalling and inflammatory molecules to the adjacent 
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bone areas (41). This explains why particle disease can expand and be found 
in different sites, leading to a spread and expansion of osteolysis, with 
consequent progressive deterioration of the bone-prosthetic interface (41). 
Wear particles from UHMWPE are responsible for the recruitment and 
activation of macrophages within the tissue, producing inflammatory factors 
as GM-CSF, macrophage-colony stimulating factor (M-CSF), PDGF, MMPs, 
prostaglandin E2 (PGE2), IL-6, IL-3, IL-1 and TNF-α (40, 43). This contributes 
to a local inflammatory and osteolytic environment surrounding the implant 
(43). Both IL-1 and TNF-α contribute to the activation, survival and 
differentiation of osteoclasts (44). Local fibroblasts also contribute to the bone 
resorption and destruction by promoting the formation of osteoclasts, through 
the expression of the receptor activator of nuclear factor kappa-B ligand 
(RANKL) (45). The macrophages attempted response at degrading these 
particles by phagocytising them, is ineffective because these are both 
biologically inert and non-degradable (46). Thus the macrophages keep 
releasing the aforementioned cytokines and mediators, exacerbating and 
perpetuating the osteoclastic process (32, 41). 
UHMWPE wear particles osteolytic potential is dependent on both particle 
size and volume. Particles in the size range of 0.1–1.0 µm are more 
biologically active than larger particles in terms of osteolytic cytokine release 
(46). The currently used crosslinked UHMWPEs produce smaller particles 
(<0.1 µm) in large numbers (47). They have a smaller wear volume than the 
one from the conventional THA, but can be systemically disseminated, with 
UHMWPE wear particles being found in the lymph nodes, spleen and liver 
(48). These particles trigger a different biological response than the original 
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ones, their effect in the local osteolysis being unclear, as well as if they are 
associated with any kind of systemic effects like the ones that happen with 
metallic particles/ions (49). Although they appear to be inactive in stimulating 
proinflammatory cytokine release both locally and systemically (49), few 
reports are yet available. 
Besides crosslinked UHMWPEs, other materials, such as metals and 
ceramics have been developed as low wear alternative bearing surfaces to 
avoid particle-induced osteolysis (49). 
Metals like CoCr produce large amounts of nanometer-sized particles through 
wear and corrosion (50). Their large number and small size have increased 
risk of cytotoxic, genotoxic and immunological impact in both local and distant 
organs, as they can be absorbed and were already found systemically in bone 
marrow, lymph nodes, liver and spleen (48). They cause increased 
concentration of free radicals and Chromium concentrations, with effects in 
both cell death and mutagenesis properties, through damage of intracellular 
organelles and deoxyribonucleic acid (DNA). Clinical studies of surrounding 
tissues on metal on metal (MoM) implants have demonstrated increased 
levels of translocations, aneuploidy and DNA damage (51). However no 
evidence between the use of these prosthetic materials and cancer 
occurrence was found in previous epidemiological studies (52). MoM implants 
have been demonstrated to cause less osteolysis than implants using 
UHMWPE, because most of the wear particles identified in these implants are 
less than 100 nm in size, and thus much smaller than the UHMWPE particles 
(50). In these cases ostelysis is usually related to patient’s metal 
hypersensitivity (32, 41). 
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Ceramics are the hardest biomaterial implant developed for THA, with a wear 
rate 1000-fold lower than UHMWPE-Metal implants (53). It is also highly 
durable and has little or none known toxic effects (54). In normal conditions 
their debris range from 5–25 nm. A greater number of particles and debris, 
with sizes of 14–70 µm particles, can occur in cases of damage to 
components due to localized overloading or scuffing in cases of mal alignment 
or trauma (54).  
The research comparing the biological response of ceramic wear particles 
with UHMWPE and metal particles is limited. Nevertheless it is unlikely that 
the necessary amount of particles needed to create the same responses can 
be achieved in vivo, considering the wear rates reported for ceramics (32). 
Taking in consideration that patients having the same kind of surgery and 
implants, with comparable radiographic alignment and physical activity, do not 
present the same responses as the ones described above, reinforces the 
possibility than some kind of individual susceptibility to periprosthetic 
osteolysis can exist, despite the fact that its risk factors and pathways are still 
unclear (41). 
 
Influence of the Neuroimmune Axis in Joint Diseases 
The processes previously described have been explained by detailing the 
individual events that are involved in both HOA and THA failure, specifically at 
a local level in the hip joint. Despite the great progresses made in the 
characterization of these events, the systemic impact of local events, as well 
as their regulation, remains unclear. 
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In previous years, attention has been given to the role of the neuroimmune 
axis and neurogenic stimuli in the interaction and interrelation between 
immune cells and cytokines with different systems and environments (55). 
Current literature demonstrates the influence of neuroimmune axis and 
neurogenic stimuli in inflammation and cytokines expression, immune cells 
proliferation and migration, matrix synthesis and degradation, angiogenesis 
and connective tissues synthesis (56). 
These advances in research raised questions regarding the influence of the 
neuroimmune axis in the pathogenesis of both hip osteoarthritis and aseptic 
loosening. 
Over the past decades, accumulated evidence has pointed to the role of 
peripheral nervous system and its neurotransmitters as critical players in the 
pathophysiology of several joint articular diseases (26, 27). In healthy joints, 
under physiological conditions, sensory and sympathetic nerve fibers have 
been found in bone, periosteum and synovial tissue, but there are no reports 
of their presence in healthy cartilage (57). However, despite the lack of 
innervation, cartilage and joint development are modulated and influenced by 
neurotransmitters released either from nerve fibers located in neighbouring 
tissue, or directly from chondrocytes (57). SP, CGRP and sympathetic 
neurotransmitters affect chondrogenic differentiation and metabolism of 
chondroprogenitor through specific receptors for sensory neuropeptides, 
neurokinin 1 receptor, CGRP receptor and sympathetic β2-adrenoceptor (57). 
Under pathological conditions, the joint displays different patterns of 
innervation. Rheumatoid arthritis (RA) is characterized by changes in the 
density of sensory and sympathetic nerve fibers in the synovial tissue (58),  
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with an increase in SP nerve neurotransmitters together with a decrease in 
CGRP, adenosine and norepinephrine concentrations (58).   
In the early stages of OA both sensory and sympathetic nerve fibers migrate 
into the cartilage. With OA development, an increase of sensory fibers when 
compared to sympathetic fibers is found, with both SP and CGRP nerve fibers 
present in a balanced way (59). This differs from RA, with a preponderance of 
SP fibers and a marked reduction of CGRP and sympathetic fibers (58, 59).  
Sensory and sympathetic nerve fibers have an important role in chronic 
inflammation regulation in RA, as SP is known to have a pro-inflammatory role 
by increasing the concentrations of IL1, IL6 and TNF (60), while CGRP and 
sympathetic neurotransmitters present a anti inflammatory role by inhibiting 
these cytokines actions (61, 62).  
Saxler et al first reported the increased presence of CGRP and SP nerve 
fibers in the articular cartilage of symptomatic patients with HOA, when 
compared to controls (63).  Suri et al reported the same in the knee, and 
described that the nerves are in perivascular localization (64). Salo et al 
indicated that SP and CGRP presence precedes cartilage degeneration (65). 
SP is up-regulated in response to mechanical stimulus in OA patients, what 
might indicate a role of this peptide in the maintenance of cartilage function 
and integrity (66).   
In another hand, SP has been reported to play a major role as strong effector 
in the inflammatory response under the development of OA (57, 67). 
Increased SP in adult synovial fluid in OA patients was associated with 
catabolic effects on articular cartilage, and this increase could be promoted by 
TGF-β and FGF (67). These catabolic effects are related to an increase in IL-
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1βn, TNF-α and MMPs concentrations and a simultaneous reduction in 
proteoglycans deposition (68).  
CGRP actions are currently less well known, with contradictory information in 
the literature regarding its actions in chronic inflammation. Fox et al describe 
an anti-inflammatory by inhibiting macrophage activation and action (69). 
Dirmier et al presented a diminished presence of CGRP in synovial tissues of 
RA patients as a factor for a pro inflammatory status, describing the actions of 
CGRP as anti-inflammatory (58), while Walsh et al suggest CGRP as a factor 
contributing for pain and inflammation in chronic arthritis, by augmenting the 
release of SP and pro-inflammatory cytokines from macrophages (70).  
Takeshita et al found a significant increase in sensory innervation and pro-
inflammatory cytokines, as TNF-α, in HOA patients, when compared with non-
OA patients (71). According to this study, TNF-α is released from nerve fibers 
besides macrophages and T cells, with a role in inducing neural ingrowth in 
addition to its known inflammatory proprieties (71).  
Sympathetic nerve fibers have also been associated with physiological 
processes as bone remodelling, metabolism, mineralization, osteogenesis, 
and matrix differentiation (67). Moreover, they have been implied in the 
development of OA, by influencing bone and cartilage differentiation, 
remodelling and regeneration capacity, as well as eliciting significant effects in 
both osteoclasts and osteoblasts activity (57, 67).  
The activation of the sympathetic nervous system in the context of 
inflammation results in the release of high amounts of sympathetic 
neurotransmitters, such as neuropeptide Y (NPY) and norepinephrine (NE), 
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known to induce an anti-inflammatory effect in a context-dependent manner 
(72). 
The mechanism of anti-inflammatory action of sympathetic nervous system in 
arthritis is not completely understood, but possible mechanisms have been 
described in animal models. Stimulation of β2-adrenergic receptors (β2-ARs) 
on B cells by catecholamines, results in increased IL-10 production from these 
cells, and diminished proinflammatory activity by inhibiting IL-7 receptor (73) 
In THA aseptic loosening, previous reports have mentioned the involvement 
of sensory nerve fibers in the regulation of the inflammatory processes and 
bone resorption, through local release of neuropeptides (74-76). In these 
cases, SP and CGRP nerve fibers were identified in the interface membrane 
of AL patients (75). SP was shown to raise local levels of IL-1 and TNF-a (76), 
with subsequent increase in osteoclastic response. However, we know little 
regarding the actions of the sensory nervous system and even less regarding 
the sympathetic nervous system. 
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Aims of the Thesis 
The main objective of this PhD Thesis was to investigate the involvement of 
the neuroimmune axis in the biological events leading to hip osteoarthritis and 
aseptic loosening. 
 
Thereby, the following specific objectives were defined: 
1) Assess the nervous and immune system profile of patients with hip 
osteoarthritis when compared to healthy controls 
We performed the first systematic review assessing the nervous and immune 
system profile, both at a local and systemic level, of patients with hip 
osteoarthritis when compared to healthy controls.  
 
The results are presented in Chapter II: 
“Neuroimmune expression in hip osteoarthritis: a systematic review.” 
da Silva MR, Linhares D, Vasconcelos D, Alves CJ, Neves N, Costa G, 
Lamghari M.  
BMC Musculoskelet Disord. 2017 Sep 11;18(1):394. doi: 10.1186/s12891-
017-1755-2.  
 
2) Characterize the immune and innervation profiles of hip aseptic loosening 
patients when compared with patients with hip osteoarthritis 
We investigated the local tissue inflammatory response, sensory and 
sympathetic innervation as well as associated local mediators in hip joint 
microenvironment underlying hip aseptic loosening when compared to 
osteoarthritis.  
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The results are presented in Chapter III: 
“Immune response and innervation signatures in aseptic hip implant 
loosening.” 
Vasconcelos DM*, Ribeiro-da-Silva M*, Mateus A, Alves CJ, Machado GC, 
Machado-Santos J, Paramos-de-Carvalho D, Alencastre IS, Henrique R, 
Costa G, Barbosa MA, Lamghari M.  
J Transl Med. 2016 Jul 7;14(1):205. doi: 10.1186/s12967-016-0950-5. 
* equal contribution 
 
3) Characterize the impact of aseptic loosening in the activity of the 
sympathetic nervous system  
We evaluated the systemic and local profile of neuroimmune molecules 
involved in the interplay between the sympathetic nervous system and the 
periprosthetic inflammation in hip aseptic loosening. 
 
The results are presented in Chapter IV: 
“Interplay between sympathetic signaling and inflammation in aseptic 
loosening of hip joint replacement” M. Ribeiro-da-Silva, D.M. Vasconcelos, 
I.S. Alencastre, M.J. Oliveira, D. Linhares, N. Neves, G. Costa, R. Henrique, 
M. Lamghari, C.J. Alves.  
Sci Rep. 2018 Oct 8:16044. doi: 10.1038/s41598-018-33360-8.  
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Abstract 
Background 
Neuroimmune axis is central in the physiopathology of hip osteoarthritis (OA), 
but its specific pathways are still unclear. This systematic review aims to 
assess the nervous and immune system profile of patients with hip 
osteoarthritis (OA) when compared to healthy controls. 
Methods 
A systematic review followed PRISMA guidelines was conducted. A two-step 
selection process was completed, and from 609 references 17 were included. 
The inclusion criteria were: original articles on adult patients with hip OA, with 
assessment of neuroimmune expression. Articles with other interventions 
prior to analysis and those without a control group were excluded.  
Results 
Thirty-nine relevant neuroimmune markers were identified, with assessments 
in bone, cartilage, synovial membrane, synovial fluid, whole blood, serum 
and/or immune cells. GM-CSF, IFN-γ, IL-1α, IL-6, IL-8, IL-1 and TNF-α 
presented variable expression among tissues studied when compared 
between hip OA and controls.  VEGFs and TGF-ß isoforms showed similar 
tendencies among tissues and studies. On nervous expression, CGRP, Tuj-1 
and SP were increased in synovial membrane. Overall, patients with hip OA 
presented a higher number of overexpressed markers. 
Conclusions 
For the first time a systematic review on neuroimmune expression in patients 
with hip OA found an upregulation of neuroimmune markers, with deregulated 
balance between pro and anti-inflammatory cytokines. However, no clear 
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systematic pattern was found, and few information is available on nervous 
expression. This highlights the importance of future research with clear 
methodologies to guide the management of these patients. 
 
Keywords: Hip osteoarthritis; Neuroimmunomodulation; Inflammation; 
Cytokines 
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Background 
Hip osteoarthritis (OA) is a common chronic health condition and a leading 
cause of pain and disability among adults, impacting many health outcomes 
(1). The complex and multifactorial nature of hip OA is nowadays under the 
spotlight, and recent studies proposed a switch of the paradigm from a simple 
“wear and tear” to a much more complex mechanism, in which inflammatory 
mediators play a pivot role in initiation and progression of the pathologic 
process (1, 2). 
Neuroimmune axis is known to control the development and perpetuation of 
multiple inflammatory diseases (1, 3). Immune cells and secreted cytokines 
have been established as important players in OA (4). Also, neuropeptides 
were recently proposed as critical molecules in the modulation of the 
inflammation and pain associated with OA (5). Recent works showed that 
each joint should be seen as an individual organ, with OA being not 
exclusively a disorder of articular cartilage, but also an organ failure, involving 
the whole joint with additional abnormalities especially in bone, ligaments, 
synovium and joint capsule  (6-8). In particular, the understanding of the role 
of the nervous system, immune cells and cytokines in the pathophysiology of 
OA of the hip joint, and their association with the different clinical features of 
the disease is still limited (4, 9). 
Although many studies are available on particular aspects of the role of 
immune system in pathologic mechanisms in hip OA (10), there are still no 
consistent reports, and no data is available on the general profile of 
neuroimmune expression in these patients. Few studies have addressed the 
cytokine profile in hip OA, and even those, focus only on a small set of 
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cytokines and in a limited range of samples (blood, bone, cartilage or synovial 
tissue). Moreover, the global picture of hip OA neuroimmune expression is yet 
to be defined. Therefore, there is a critical need for enlightening on the role of 
neuroimmune mediators produced at the hip joint in OA patients. This 
knowledge would be of utmost importance in the ongoing study of pathologic 
pathways underlying hip OA and an important step in the development of 
disease-specific modifying therapies. 
This systematic review aims to characterize the local and systemic expression 
of neurochemical and immune biomarkers in patients with hip OA when 
compared to healthy controls. 
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Methods  
Literature Search 
A systematic search was performed in Pubmed using as main search terms: 
“neuroimmunity”, “osteoarthritis” and “hip”, and other equivalent terms. The 
limits used were a) English, French or Portuguese language, b) publication 
date from 2000 to March 2015, c) studies performed in humans, d) exclusion 
of reviews, editorials and comments. 
 
Article Selection 
Study selection was conducted in two phases (Figure 1). In Phase 1, two 
investigators screened the titles and abstracts independently. If one of them 
included the abstract, it was allowed into the Phase 2. In Phase 2, full-text 
articles were analyzed independently, and disagreements were discussed 
between reviewers. Inclusion criteria were: 1) original data; 2) data on 
neuroimmune expression; 3) patients with hip OA; 4) adults (>18 years old). 
Exclusion criteria were:  1) studies performed in tissues other than the hip; 2) 
participants with known main diseases other than hip OA, e.g. rheumatoid 
arthritis; 3) patients or samples submitted to intervention prior to the analysis 
that may influence the results; or 4) absence of a control group. When 
manuscripts or data were not available, the authors were contacted. One 
study was excluded because results on cytokine expression were outside the 
range described by the manufacturer of the technique use and no answer on 
clarification from the author was received until the end of data analysis. 
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Figure 1. Selection Process 
 
Data Extraction 
Data was extracted using an electronic form developed by the authors and 
general article information is on Table 1. 
The study group was defined as patients with hip OA, upon a diagnosis based 
on clinical, radiological and/or histological analysis. Controls were defined as 
healthy patients without OA diagnosis (hip or another).  
Studies were grouped based on the technique used for neuroimmune 
expression measurements, namely: Bead-based multiplex immunoassay, 
Enzyme-Linked Immunosorbent Assay (ELISA), quantitative real-time 
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polymerase chain reaction (qRT-PCR) or immunostaining; and based on the 
sample used: synovial fluid, synovial membrane, cartilage, whole blood 
(blood), serum, immune cells, or bone. In each individual subgroup values 
were compared between patients with OA and controls (Supplementary Table 
1).  
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Table 1. Description of the sample and methods of the studies included and hip OA assessment 
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Data analysis 
Data was gathered on the significance of the comparisons, with a significant 
statistical value being defined as p<0.05. 
Ratios on neuroimmune expression between hip OA and control patients were 
computed, and a visual illustration with arrows was assembled, grouped by 
tissue sample (Table 2). If different measurement techniques resulted in 
different ratios, these were all displayed. A general immune expression 
pattern was also displayed for each tissue (Figure 2). 
Only 2 studies were available for the same immune marker when grouped by 
tissue and technique, and no meta-analysis was performed, since high 
heterogeneity was predictable. 
This systematic review follows the PRISMA recommendations and PRISMA 
checklist was completed and is available on Supplementary Table 2 (11).	
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Results  
Articles’ search retrieved a total of 609 references. After limits applied 358 
were included in the final review. In the first selection phase, 228 articles were 
excluded, mainly studies with patients with other known conditions than hip 
OA (Figure 1). In the second selection phase, all but 4 full-text articles were 
retrieved and analyzed. Seventeen studies were included in the systematic 
review (5, 9, 12-26). Twelve were cross-sectional studies, three cohorts, and 
one a case-control. Apart from one, all studies primary goal was neuronal 
and/or immune expression analysis. All were hospital-based studies, with 
outpatient clinic recruitment. Sample sizes ranged from 6 to 128 participants 
(Table 1).  
Most studies (n=14) based OA diagnosis on clinical and radiological 
evaluation; one only had a clinical diagnosis, and two also had a histological 
analysis. Controls definition was highly variable and mostly based on clinical 
examination and X-ray. Individuals with non-OA hip fracture were used as 
healthy controls in three studies (Table 1). 
Thirty-nine relevant neuroimmune markers were identified from the studies 
retrieved, and data on the comparison between patients with hip OA and 
controls was gathered (Supplementary Table 1). Their expression was 
evaluated by five different laboratorial techniques. All but three articles 
reported in vivo results. The tissue samples studied in the included reports 
were bone, cartilage, synovial membrane, synovial fluid, whole blood (blood), 
serum and immune cells (Supplementary Table 1).  
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 67	
Six articles did not present numerical values on the analysis performed. Data 
on general results and significance of the comparisons was gathered when 
possible and presented (Supplementary Table 1).  
Fifteen articles reported on immune markers expression and two articles 
presented results on neurochemical expression. Only one study was available 
on neuroimmune expression in synovial fluid and in serum. Two were 
available on immune cells production and blood expression, 3 in synovial 
membrane, 4 in cartilage and 7 in bone. One article studied more than one 
tissue, with different techniques (Supplementary Table 1 and Table 2). 
The following markers showed a different variation on neuroimmune 
expression in different tissues (Table 2):  
• IFN-γ increased in synovial fluid, increased production in immune cells, 
decreased in bone; 
• IL-6, increased in synovial fluid, blood and bone, decreased production 
in immune cells; 
• TNF-α, increased in synovial membrane, cartilage, serum and blood, 
decreased in synovial fluid and decreased production in immune cells; 
• IL-10, increased in synovial membrane and cartilage, decreased in 
serum and decreased production in immune cells;  
• IL-8 is increased in synovial membrane and bone, decreased in serum; 
• GM-CSF and IL-2 increased production in immune cells, decreased in 
bone; 
• IL-1α, increased in synovial membrane, cartilage and bone, decreased 
in serum. 
 
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 68	
Similar variations in different tissues were recorded for: 
• VEGFs, increased in synovial fluid and bone; 
• -GF-ß isoforms, increased in cartilage and bone. 
The collected data was insufficient for quantitative synthesis. Only two studies 
could be used for just three markers, and so no meta-analysis was performed.  
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Table 2. Ratios on neuroimmune expression between hip osteoarthritis and 
controls according to the sample 
Ratios were computed as times raised: ↑: 1–1.25; ↑↑: 1.25–1.50;↑↑↑: 1.50–2; ↑↑↑↑: 
>2; and times decreased: ↓: 1–0.8; ↓↓: 0.8–0.67; ↓↓↓: 0.67–0.5; ↓↓↓↓: <0.5. When 
values are not available a single arrow (when statistically significant) or = (when non 
significant) was displayed. Data on statistically significance weren’t available or 
statistically significant, unless indicated as *p < 0.05 SF synovial fluid, SM synovial 
membrane, Blood Whole Blood, hOA hip Osteoarthritis, C Controls. aPCR and 
Immunohistochemestry. bValues not available 	  
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Table 3. General pattern of neuroimmune expression 
Analysis presented was based on articles general results. When 2 articles had conflicting data on 
expression or when comparisons were stated as non-significant data was assigned as doubtful or equal  ! VEGFs, increased in synovial fluid and bone;
! -GF-ß isoforms, increased in cartilage and bone.
The collected data was insufficient for quantitative
synthesis. Only two studies could be used for just three
markers, and so no meta-analysis was performed.
Discussion
Recent studies showed the joint-specific character signa-
ture of the immunity and nervous system activity under-
lying OA [27]. This is the first systematic review on the
neuroimmune expression of patients with hip OA. Few
articles were available, and even fewer when sorted
among samples studied. Most of the literature regarding
hip OA is focused on the immune response and patho-
logical changes of immune mediators. On neurochemical
expression, only two articles that meet our inclusion cri-
teria were retrieved. Both showed a tendency to neuro-
peptide overexpression in synovial membrane [5, 25].
Although this review did not found any specific sys-
tematic pattern in each individual tissue, some tenden-
cies on the general neuroimmune expression were
observed. Pro-inflammatory cytokines such as IL-6,
TNF-α and IL-8 were found local and/or systemically in-
creased in the context of hip OA. Particularly, IL-6 is lo-
cally increased in synovial fluid and bone, and also
systemically in blood. IL-6 is a pro-inflammatory cyto-
kine, that acts as a stimulator of osteoclast recruitment
and bone reabsorption, being related with altered bone
metabolism previously described in OA [28, 29]. This
goes along with previous works postulating OA as a
pro-inflammatory condition [1, 2], and is reinforced by
the significant raise of other pro-inflammatory cytokines,
such as TNF-α and IL-8. TNF-α was found augmented,
both systemic and locally, in synovial membrane, cartil-
age, bone and blood. It acts both as a mediator of matrix
degradation [30] and as an intermediate between im-
mune and nervous system. It is associated with nocicep-
tive response and induces neuronal ingrowth [25, 31].
IL-8 was found increased in both bone and synovial
membrane, presenting a pattern of expression similar to
IL-1.
IL-10 and IL-4 are known anti-inflammatory cyto-
kines. Previous works reported that they are spontan-
eously produced in synovial membrane and cartilage
[30], probably in an attempt to locally control the in-
flammatory process [9, 30]. This review supports the
findings on IL-10, which is increased in both tissues, but
no information was retrieved on IL-4 expression in hip
OA patients. Also, the systemic decrease of these anti-
inflammatory markers in serum and immune cells,
reinforce the ongoing idea of a shift towards a pro-
inflammatory state, already reported in hip OA [1, 2].
A local response on cartilage and bone was also ob-
served when analyzing TGF-ß family cytokines. TGF-ß
is an inductor of chondrocyte anabolic response and is
Table 3 General pattern of neuroimmune expression
Sinovial Fluid Synovial Membrane Cartilage Serum Immune Cells Blood Bone
Increased IFN-γ
IL-6
MCP-1
MIP-1β
VEGF
IL-10
IL-1α
IL-8
TNF- α
TGF-β1
TGF-β2
TGF-β3
CGRP
NF-Kb
TuJ-1
SP
IL-10
IL-1α
TNF- α
TGF-β1
TGF-β2
TGF-β3
TNF- α BAFF
GM-CSF
IFN-γ
IL-2
IL-6
OPG
TNF- α
BMP-1
BMP-6
ICAM
ICAM-3
IL-6
IL-8
PGE-2
TGF-β1
TGF-β2
TGF-β3
Doubtful or Equal IL-8
Il-1β
Il-1β
TGF-β
TGF-βR1
TNF- α
Decreased IL-1Rα
Il-1β
PDGF-ββ
RANTES
TNF-α
IL-8 IL-10
IL-4
IL-6
TNF- α
IL-10
IL-1α
RANKL
BMP-5
GM-CSF
IFN-γ
IL-10
IL-12
IL-1α
IL-2
IL-4
IL-5
VEGF-b
VEGF-c
Analysis presented was based on articles general results. When 2 articles had conflicting data on expression or when comparisons were stated as non-significant
data was assigned as doubtful or equal
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Discussion  
Recent studies showed the joint-specific character signature of the immunity 
and nervous system activity underlying OA (27). This is the first systematic 
review on the neuroimmune expression of patients with hip OA. Few articles 
were available, and even fewer when sorted among samples studied.  Most of 
the literature regarding hip OA is focused on the immune response and 
pathological changes of immune mediators. On neurochemical expression, 
only two articles that meet our inclusion criteria were retrieved. Both showed a 
tendency to neuropeptide overexpression in synovial membrane (5, 25).  
Although this review did not found any specific systematic pattern in each 
individual tissue, some tendencies on the general neuroimmune expression 
were observed. Pro-inflammatory cytokines such as IL-6, TNF-α and IL-8 
were found local and/or systemically increased in the context of hip OA. 
Particularly, IL-6 is locally increased in synovial fluid and bone, and also 
systemically in blood. IL-6 is a pro-inflammatory cytokine, that acts as a 
stimulator of osteoclast recruitment and bone reabsorption, being related with 
altered bone metabolism previously described in OA (28, 29). This goes along 
with previous works postulating OA as a pro-inflammatory condition (1, 2), 
and is reinforced by the significant raise of other pro-inflammatory cytokines, 
such as TNF-α and IL-8. TNF-α was found augmented, both systemic and 
locally, in synovial membrane, cartilage, bone and blood. It acts both as a 
mediator of matrix degradation (30) and as an intermediate between immune 
and nervous system. It is associated with nociceptive response and induces 
neuronal ingrowth (25, 31). IL-8 was found increased in both bone and 
synovial membrane, presenting a pattern of expression similar to IL-1.  
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IL-10 and IL-4 are known anti-inflammatory cytokines. Previous works 
reported that they are spontaneously produced in synovial membrane and 
cartilage (30), probably in an attempt to locally control the inflammatory 
process (9, 30). This review supports the findings on IL-10, which is increased 
in both tissues, but no information was retrieved on IL-4 expression in hip OA 
patients. Also, the systemic decrease of these anti-inflammatory markers in 
serum and immune cells, reinforce the ongoing idea of a shift towards a pro-
inflammatory state, already reported in hip OA (1, 2) 
A local response on cartilage and bone was also observed when analyzing 
TGF-ß family cytokines. TGF-ß is an inductor of chondrocyte anabolic 
response and is antagonized by IL-1, that acts as a stimulator of cartilage 
degradation (18, 32).  Accordingly, both TGF-ß1, - ß2 and -ß3 and IL-1 
isoforms were found increased in these tissues. However, no data on the 
systemic expression of TGF-ß was retrieved, and although one article 
reported a systemic decrease of IL-1 expression (9), these results were not 
significant, supporting the theory of a tendency to a local action of IL-1, with 
no measurable systemic repercussion (33, 34).  
RANKL is an osteoclastogenic factor that triggers a cascade of intracellular 
events, essential to osteoclast activation and differentiation. OPG is a RANKL 
decoy receptor and limits its biologic activity. Therefore, OPG activation 
suppresses osteoclast differentiation, inhibits their activation and induces 
apoptosis (14). Granchi et al described an increased expression of OPG in hip 
OA patients, stating that elevated OPG levels may reflect a protective 
mechanism of the skeleton to compensate for the osteolytic activity that 
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occurs in severe osteoarthritis (14). However, in this article, RANKL 
expression comparisons were not statistically significant (14). 
The two articles retrieved on neurochemical expression in patients with hip 
OA, reported a raise of CGRP, Tuj-1 (neuron-specific class III ß-tubulin) and 
SP in synovial membrane (5, 25).   
The role of nerve fibers and their neurotransmitters in cartilage, subchondral 
bone, and other joint tissue function and homeostasis is becoming more 
evident, with reports on the peripheral nervous system involvement in the 
pathogenesis of disorders such as OA. Suri et al. reported the presence of 
both sensory (SP- and CGRP-positive) and sympathetic nerve fibers 
(neuropeptide Y (NPY)-positive) in the articular cartilage, within vascular 
channels, in both mild and severe stages of knee OA. The exclusively 
perivascular localization of nerves in the surface layer of articular cartilage 
implies vascularization as a driving force behind its innervation (35). Nerve 
growth is associated with peripheral sensitization. Accordingly, the presence 
of nerves in structures such as cartilage that are not normally innervated 
could expose them to chemical stimulation and mechanical stress, explaining 
why perivascular nerve growth might contribute to the pain mechanisms in OA 
(8), and particularly in hip OA (5). 
Tuj-1 is a neuron-specific class III ß-tubulin that was found in the synovial 
membrane of patients with hip OA, being absent in the normal controls (31). 
The expression of this neurochemical marker occurs after blood vessels and 
nerve fibres ingrowth from the inflammation of synovial tissue. These 
inflammatory mechanisms are probably associated with the pain complaints of 
patients in hip OA (36). 
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Clinical data from OA patients supports an association between CGRP-
immunoreactive fibers and pain (37). This review retrieved two articles 
showing an increased expression of this neuronal marker in patients with hip 
OA, what may also be associated with the pain mechanisms in this condition. 
Additionally, in other diseases, such as hip dysplasia, increased levels of SP 
and CGRP were detected in synovial tissue and fluid and were associated 
with catabolic and pro-inflammatory effects (38). SP, also found increased in 
hip OA patients, was implicated in the modulation of the physiological 
metabolism of chondrocytes and cartilage homeostasis, with catabolic effects 
on articular cartilage during OA (39).  
This is corroborated by other works stating the importance of these peptides 
in modulation of the inflammatory process and in signaling of pain in OA (40), 
being increased in all stages of inflammation (41).  
Overall, our review goes along with previous reports on OA, with no relevant 
differences found between hip OA neuroimmune expression and the one 
reported in general OA patients (24). A recent review on immune expression 
showed a tendency towards an overexpression of cytokines in patients with 
OA, with a role for inflammation in the disease severity and progression (4). 
Our review confirms these results, showing an overall increase of cytokine 
expression in OA and reinforcing the idea of a link between a deregulated 
function of the neuroimmune system and the development and perpetuation 
of the disease (4). Nevertheless, no specific systematic pattern on 
neurochemical changes in OA was found. This work brings light on the need 
to further studies on the neuroimmune axis in joint-related conditions, as its 
role is yet to be clearly defined. 
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The individual methods found in the retrieved works were heterogeneous. 
Some studies provided no definition for the control group, and others used 
patients with proximal femur fractures as controls. Even if stated by individual 
authors that no OA was observed when this last group was used as control, 
one cannot exclude both the influence of the fracture itself and the possible 
influence of concomitant milder undiagnosed forms of OA. Patients affected 
with proximal femur fractures are elderly subjects, which can be affected by 
milder forms of hip OA, with local and systemic biochemical changes before 
the time a radiological diagnosis of hip OA is made (42). Also, fractures, due 
to the inherent aggression, are associated with both a local and a systemic 
biochemical response, with an increased inflammatory response (43). Both 
undiagnosed hip OA and the fracture-associated inflammatory reaction can 
lead to an underestimation of the neuroimmune activation in patients with hip 
OA, which represents an import bias in these comparisons (42). Furthermore, 
it is known that expression of individual molecules changes along OA 
progression. Since many articles do not state the stage of the disease in 
which each sample collected, one cannot reliably assure that the comparisons 
established refer to similar timing of the disease, what can have a major 
impact in the results presented. Lastly, the revised studies used different 
methodologies to assess the targets across the analyzed tissues. Thus, the 
sensitivity (e.g. ELISA vs Lumina(R) Multiplex) and the evaluated form of the 
target (e.g. mRNA vs. protein) limits the reliability of a molecular hip OA profile 
(44). 
Our study has some limitations. Firstly, a quantitative data synthesis by meta-
analysis was not possible, as only a few studies were available in each 
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 77	
molecule expression for a specific tissue, with different outcome 
measurements. Also, most studies included a small number of patients, a 
problem also stated in a previous review, that implies a need for future 
confirmation of these data in additional studies or in larger cohorts (4). Some 
studies reported results only from qualitative outcomes, and others do not 
report the significance of their quantitative results. This further impacts our 
ability to properly analyze their results. As stated before, one study was even 
excluded since no reliable data was provided. 
Nevertheless, this is the first available systematic review on neuroimmune 
expression in human patients with OA, and especially with hip OA, without 
any limitation for sample size, age group, sex or type of sample studied. Two 
blinded reviewers analyzed the articles in each review phase, diminishing the 
risk of selection bias. Only 4 full-texts were not available, with high full-text 
article retrieval rate.  
Future studies with strictly defined rules on control and patient selection, as 
well as disease progression stage, demographic characteristics of samples, 
sample collection, processing and analysis are needed. As stated by previous 
reports, a correlation with clinical features of the disease may also be a 
valuable resource in future strategies for directing therapy investigations (4). 
Few information was available on neurochemical activity in these patients, 
and in what comes to immune system, most studies focus only on classic 
cytokines. New and more information on different and recent found targets are 
required (2, 11, 45). Also, and particularly for hip OA, there is a need to study 
the role of neuroimmune expression on the functional impairment and pain 
levels reported by these patients. It is also important to have a previously 
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defined set of molecules with central roles in this disease, to have a more 
uniform report among future works. Larger samples are needed to provide 
more reliable results. 
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Conclusions 
This is the first systematic review available on neuroimmune expression on 
hip OA and highlights a key role of inflammation in both disease maintenance 
and progression. It is associated with an overall upregulation of the 
neuroimmune system, confirming previous reports on a deregulated balance 
between pro and anti-inflammatory cytokines, both locally and systemically, 
impacting cartilage and bone remodelling. This review enhances the 
importance of further studies with a simultaneous assessment on immune and 
neurochemical expression in these patients, following clearly defined criteria 
and similar methodological strategies.   
  
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 80	
Declarations 
Availability of data and materials 
The datasets generated and/or analysed during the current study are not 
publicly available but are available from the corresponding author on 
reasonable request. 
 
Funding 
This article was financed by the project NORTE-01-0145-FEDER-000012, 
supported by Norte Portugal Regional Operational Programme (NORTE 
2020), under the PORTUGAL 2020 Partnership Agreement, through the 
European Regional Development Fund (ERDF). DMV was supported by the 
Ph.D. fellowship SFRH/BD/87516/2012 financed by FCT - Fundação para a 
Ciência e Tecnologia. 
 
Competing Interests 
All authors declare no competing interests in the development and publication 
of this study. 
 
Authors' contributions 
MRS contributed to study conception and design, acquisition of data, analysis 
and interpretation of data, drafting of the manuscript, critical revision and final 
read and approval upon submission. DL contributed to study conception and 
design, acquisition of data, analysis and interpretation of data, drafting of the 
manuscript, critical revision and final read and approval upon submission. DV 
contributed to study conception, analysis and interpretation of data, drafting of 
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 81	
the manuscript, critical revision and final read and approval upon submission. 
JA contributed to interpretation of data, drafting of the manuscript and final 
read and approval upon submission. NN contributed to interpretation of data, 
drafting of the manuscript and final read and approval upon submission. GC 
contributed to study conception, interpretation of data, drafting of the 
manuscript and final read and approval upon submission. ML contributed to 
study conception and design, interpretation of data, drafting of the manuscript, 
critical revision and final read and approval upon submission. 
 
Ethics 
Not applicable. 
 
Consent to publish 
Not applicable. 
  
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 82	
Additional Files 
	
Additional	File	1	
 
  
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 83	
 
 
 
  
	 	 Techni
qu
e	
Sa
m
pl
e	
Ar
t.	
Gr
ou
p	
BA
AF
	
BM
P-
1	
BM
P-
5	
BM
P-
6	
CG
RP
	
GM
-C
SF
	I
CA
M
	I
CA
M
-3
	I
FN
-γ
	
IL
-1
0	
Il-
12
	
IL
-1
Rα
	
IL
-1
α	
Il-
1β
	
IL
-2
	
IL
-4
	
IL
-5
	
IL
-6
	
IL
-8
	
M
CP
-1
	M
IP
-1
β	
N
F-
K
b	
O
PG
	
PD
GF
-β
β	
PG
E-
2	
RA
N
K
L	
RA
N
TE
S	
SP
	
TG
F-
β	
TG
F-
β1
	
TG
F-
β2
	
TG
F-
β3
	
TG
F-
βR
1	
TN
F-
α	
Tu
J-
1	
VE
GF
	V
EG
F-
b	
VE
GF
-
c	
Be
ad
-b
as
ed
	
m
ul
ti
pl
ex
	
im
m
un
oa
ss
sa
y	
(μ
g/
m
L)
	
	
SF
	
Abram
s,	2014
	
[10]	
hOA	
	
	
	
	
	
	
	
	19
9.12	 (188.9
)		
	11
08.07	 (1032.
1)		
11.36	 (11)& 	
	
	
	18
2.5	 (93.4)	
	44
.04	 (25)	
26	(13
)		
	5
6.87	 (22)	
	
	18
8.08	 (49.4)	
	
	
		
		
79.22	 (70.6)	
	258
.17	 (60.2)	
	
	
C	
	
	
	
	
	
	
	
	15
1.06	 (123.2
)		
	40
26.03	 (3183.
3)		
13.12	 (11.9)&
		
	
	61
.3	 (30.4)	
	35
.93	 (12.1)	
9	(4)	
	
	2
70.71	 (151)	
	
	34
1.95	 (85.5)	
	
	
		
		
198.25
	
(140.7
)		
140.52
	
(38.2)	
	
	
SM
	
Hulejo
va,	
2007#	 [
7]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	2
.4	 (2.8)	
	
	
	
	
	
	
	
	
	
	
		
		
1.9	 (0.5)	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	0
.4	 (0.3)	
	
	
	
	
	
	
	
	
	
	
		
		
0.8	 (0.1)	
	
	
	
	
C	
Hulejo
va,	 2007	[7
]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	1
3.5	 (4.1)	
	
	
	
	
	
	
	
	
	
	
		
		
2.5	 (0.5)	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	1
6.4	 (9.2)	
	
	
	
	
	
	
	
	
	
	
		
		
1.5	 (0.3)	
	
	
	
	
S	
Hulejo
va,	 2007	[7
]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	9
.2	 (1.4)	
	
	
	
	
	
	
	
	
	
	
		
		
11.8	 (4)	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	9
.4	 (1.1)	
	
	
	
	
	
	
	
	
	
	
		
		
8.8	 (0.7)	
	
	
	
	
Bo
	
Hulejo
va,	
2007# 	
[7]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	1
1.7	 (5)	
	
	
	
	
	
	
	
	
	
	
		
		
2.3	 (0.6)	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	1
.1	 (0.5)	
	
	
	
	
	
	
	
	
	
	
		
		
0.4	 (0.01)	
	
	
	
	
Koorts
,	
2012	[1
6]	
hOA	
	
	
	
	
	
1.96	 (7.4)& 	
	
	0.1
	(0)& 	
2.17	 (3.5)& 	
0.63	 (0.6)& 	
	
	0
.37	 (0.9)	& 	
4.07	 (10)& 	
1.24	 (3.2)& 	
1.11	 (5.8)& 	
4.37	 (3.4)& 	
16.38	 (9.6)& 	
	
	
	
	
	
	
	
	
	1
6.69	 (6.2)& 	
		
		
2.05	 (1.5)& 	
	
	
	
	
C	
	
	
	
	
	
2.58	 (10.8)&
		
	0
.18	 (0.4)& 	
4.56	 (3.9)& 	
2.73	 (5)& 	
	
	O
.49	 (1)	& 	
5.04	 (11.9)&
	1.48
	 (2.3)& 	
2.23	 (4.4)& 	
3.56	 (5.6)& 	
14.2	 (19.4)&
		
	
	
	
	
	
	
	
	
8.6	 (6.8)& 	
		
		
2.29	 (1.1)& 	
	
	
	
	
EL
IS
A	
(p
g/
m
L)
	–
	
m
ea
n	
(s
d)
	
SM
	
Hulejo
va,	
2007# 	
[7]	
hOA	
	
	
	
	
	
	
	
	
	
1.5	 (0.6)	
	
	
0.4	 (0.1)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
0.2	 (0.02)	
	
	
0.2	 (0.04)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	
Hulejo
va,	 2007	[7
]	
hOA	
	
	
	
	
	
	
	
	
	
3.3	 (1)	
	
	
0.8	 (0.3)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
0.1	 (0.01)	
	
	
0.5	 (0.1)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
IC
	
Dallos,
	
2009%
	[11]	
hOA	
685.0	 (574.8
-
809.3)
*		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	5
27.3	 (462.1
-
568.0)
*		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
Granch
i,	
2003%
	[13]	
hOA	
	
	
	
	
	
2335	 (869)	
	
	1
925	 (849)	
86	(64
)		
	
	
	1
692	 (400)	
0.1	 (0.001
)		
3008	 (894)	
	
	
	
	
	
	
	
	
	
	
	
		
		
850	 (206)	
	
	
	
	
C	
	
	
	
	
	
963	 (145)	
	
	8
61	 (266)	
434	 (141)	
	
	
	
	4
98	 (103)	
73	(18
)		
3027	 (535)	
	
	
	
	
	
	
	
	
	
	
	
		
		
1949	 (972)	
	
	
	
	
Bl
	
Granch
i,	
2006	[1
2]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	4
044	 (1932)
		
	11
15	 (1074)
		
	
	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	2
586	 (1082)
		
	16
06	 (1245)
		
	
	
		
		
	
	
	
	
	
Pape,	2
000	 [19]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	4
6	 (16)	
	
	
	
	
	
	
	
	
	
	
	
		
		
0.1	 (0.05)	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	1
2	 (18)	
	
	
	
	
	
	
	
	
	
	
	
		
		
0.07	 (0.06)	
	
	
	
	
S	
Hulejo
va,	 2007	[7
]	
hOA	
	
	
	
	
	
	
	
	
	1
7.5	 (1.9)	
	
	
4.1	 (0.5)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	 	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	2
2.0	 (2.1)	
	
	
7.3	 (0.6)	
	
	
	
	
		
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
Bo
	
Hulejo
va,	
2007# 	
[7]	
hOA	
	
	
	
	
	
	
	
	
	
1.2	 (0.6)	
	
	
0.2	 (0.05)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
0.1	 (0.01)	
	
	0
.05	 (0.01)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
Chapter	II	–	Neuroimmune	expression	in	hip	osteoarthritis:	a	systematic	review	
	 84	
	 Supp
le
m
en
ta
ry
	T
ab
le
	1
.	C
om
pa
ri
so
n	
of
	n
eu
ro
im
m
un
e	
ex
pr
es
si
on
	b
et
w
ee
n	
hi
p	
O
A	
an
d	
co
nt
ro
ls
	in
	th
e	
in
cl
ud
ed
	s
tu
di
es
	
Values
	are	gro
uped	b
y	asses
sment	
techniq
ue	and
	tissue	
studied
.	Articl
es	are	p
resente
d	as	re
ference
s	for	sp
ace	pur
poses.	
All	arti
cles	we
re	in	vi
vo,	exc
ept	for
	the	on
es	
marked
.	Data	i
s	prese
nted	w
ith	2	de
cimal	c
ases,	as
	Mean	
(Stand
ard	De
viation
),	other
wise	in
dicated
.		
*Media
n	(25th
-75th ).	
# ng/g.	
& pg/m
L.	¥ fibe
rs/cm2
.	% In	vi
tro.	$ Be
ad	base
d	multi
plex	im
munoa
ssay.	A
rt.:Arti
cle.	SF:
	synovi
al	fluid
.	SM:	sy
novial	
membr
ane.	C:	
Cartila
ge.	
Bo:	Bon
e.	Bl:	W
hole	Bl
ood.	S:
	Serum
.	IC:	Im
mune	C
ells.	hO
A:	hip	O
steoart
hritis.	C
:	Contr
ols.	NI:
	No	inf
ormati
on.	
	
Shi,	20
02%	 	 [12]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
NI	
	
	
	N
I	
	
	
	
	
	
	
NI	
	
	
	
	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
NI	
	
	
	N
I	
	
	
	
	
	
	
NI	
	
	
	
	
		
		
	
	
	
	
	
Kumar
asingh
e,	
2012%
	 	[17]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
NI	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
NI	
		
		
	
	
	
	
	
qR
T-
PC
R	
(f
ol
d-
ch
an
ge
)	
C	
Pombo
-Suarez
,	2009	 [20]	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	1.
6	1.7
	2.3	
	
	
	
	
	
	
Hashim
oto,	20
13		[14
]		
	
	
	
	
	
	
	
	
	
	
	
	
NI	
	
	
	
	N
I	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
Bo
	
Sanche
z-Saba
té,	200
9		
[21]	
	
NI	
	
NI	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	N
I	NI
	NI	
	
	
	
	
	
M
ic
ro
ar
ra
y	
(f
ol
d-
ch
an
ge
)	
Bo
	
Hopwo
od,	200
7		[15]
		
	-1
0.31	
	
	
	
	3
.30	
	
	
	
	
	
	
	
	
	2.
59	
	
	
	
	
	
	
	
	
	
	
	2.7
4		
	-4.9
2		
	
	3
.24	5
.30	
Im
m
un
os
ta
in
in
g	
(m
ed
ia
n	
ra
ng
e)
	
(all		
imunoh
istoche
mest
ry	exce
pt	artic
le	12	
-	immu
nocitol
ogy)	
SM
	
Takesh
ita,		
2012		[
23]	
hOA	
	
	
	
	
54%	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
68%	
	
	
	
	
	
	
	
		
		
58%	
46%	
	
	
	
C	
	
	
	
	
0%	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
0%	
	
	
	
	
	
	
	
		
		
0%	
0%	
	
	
	
Saxler,
		
2007		[
5]	
hOA	
	
	
	
	
15.6		 (14.3-1
8.8)¥ 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	8.
2	(6.1- 9.1)¥ 	
	
		
		
	
	
	
	
	
C	
	
	
	
	
5.7		 (3.9-7.2
)¥ 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	3.
2	(1.8- 4.2)¥ 	
	
		
		
	
	
	
	
	
Bo
	
Lavign
e,		
2004%
	[18]	
hOA	
	
	
	
	
	
	48
.6%	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	
	
	
	
	
	
	37
.5%	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
		
	
	
	
	
	
C	
Pombo
-Suarez
,	
2009	[2
0]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	++
+	++
	++	
	
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	+
+	+
	+	
	
	
	
	
	
	
Verdie
r,	
2007	[2
4]	
hOA	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	++
+	±	
+++	
++	
	
	
	
	
	
C	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	+/
++	±
	++
	+/++
		
	
	
	
	 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1. Comparison of neuroimmune 
expression between hip OA and controls in the 
includ d studies 
Values are grouped by assessment technique and 
tissue studied. Articles are presented as references 
for space purposes. All articles were in vivo, except 
for the ones marked. Data is presented with 2 
decimal cases, as Mean (Standard Deviation), 
otherwise indicated. *Median (25th-75th). #ng/g. 
&pg/mL. ¥fibers/cm2. %In vitro. $Bead based multiplex 
immunoassay. Art.:Article. SF: synovial fluid. SM: 
synovial membrane. C: Cartilage. Bo: Bone. Bl: 
Whole Blood. S: Serum. IC: Immune Cells. hOA: hip 
Osteoarthritis. C: Controls. NI: No information. 
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Abstract 
Aseptic loosening (AL) of hip prosthesis presents inflammation and pain as 
sign and symptom similarly to arthritis pathologies. Still, the immune and 
innervation profiles in hip AL remain unclear and their interplay is poorly 
explored. Herein, local tissue inflammatory response, sensory and 
sympathetic innervation as well as associated local mediators were assessed 
in hip joint microenvironment underlying AL and compared to osteoarthritis 
(OA). 
Histopathological analysis, immune cells (macrophages, T, B cells and PMNs) 
as well as sensory and sympathetic nerve fibers (Substance P+, CGRP+, 
TH+) distribution and profiles were analyzed on tissues retrieved from patients 
with failed hip prostheses due to AL (n=20) and hip OA (n=15) by 
immunohistochemistry. Additionally, transcriptional levels of pro-inflammatory 
cytokines (TNF-α, IL-1β, IL-6, IL-12a, iNOS), anti-inflammatory cytokine (IL-
10), osteoclastic factor (RANKL) and bone remodeling factor (TGF-β1) were 
locally evaluated by qRT-PCR. Serum TGF-β1 levels were assessed 
preoperatively by ELISA. 
Histopathological analysis revealed that tissues, aseptic interface membranes 
of AL patients had distinct tissue architecture and immune cells profile when 
compared to OA synovial tissues. Macrophages, T cells and B cells showed 
significant differences in tissue distribution. In OA, inflammation is mostly 
confined to the vicinity of synovial membrane while in AL macrophages 
infiltrated throughout the tissue. This differential immune profile is also 
accompanied with a distinct pattern of sensory and sympathetic innervation. 
Importantly, in AL patients, a lack of sympathetic innervation aseptic interface 
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membranes without compensation mechanisms at cellular levels was 
observed with simultaneous reorganization of sensorial innervation. Despite 
the different histopathological portrait, AL and OA patients exhibited similar 
transcriptional levels of genes encoding key proteins in local immune 
response. Nevertheless, in both pathologies, TGF-β1 expression was 
prominent in sites where the inflammation is occurring. However, at systemic 
level no differences were found. 
These findings indicate that AL patients exhibit different local inflammatory 
response and innervation signatures from OA patients in hip joint. These 
insights shed the light on neuro-immune interplay in AL and highlight the need 
to better understand this crosstalk to unravel potential mechanisms for 
targeted-therapies to improve hip joint lifetime and treatment. 
 
Keywords: osteoarthritis, aseptic loosening, prosthetic debris, immune 
response, hip innervation 
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Introduction 
Osteoarthritis (OA) has long been considered a cartilage driven “wear and 
tear” disease that may lead to hip joint failure (1, 2). The pain and diminished 
hip joint motion induced by OA may be effectively treated through primary hip 
replacement (3, 4). Unfortunately, hip replacement is not a permanent solution 
as prostheses often fail 15-25 years after primary surgery, mostly due to 
aseptic loosening (AL), infection and dislocation (5, 6). Other therapeutic 
solutions are then urgently required to expand implants’ lifetime. 
Inflammation is common to AL and OA (1, 7, 8). Immune cells and cytokines 
have been previously reported in both clinical scenarios (8-11). Synovial 
inflammation is often observed in OA patients and is frequently characterized 
by the infiltration of specific immune cell populations, such as macrophages, T 
cells and mast cells, as well as by the expression of pro-inflammatory 
cytokines, as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (7). 
Nevertheless, these findings were mostly described in studies focusing on the 
knee or in studies combining data from both knee and hip, without anatomical 
discrimination (7). On the other hand, periprosthetic joint inflammation is 
commonly known as a complex local biological response that takes place on 
synovial membrane-like interface tissues, triggered by implant released by-
products (particles and ions) (12-15). Of note, the nature, size and amount of 
released particles are recognized to define the inflammatory profile (13-16). 
While polymeric particles such as polyethylene (PE) and 
polymethylmethacrylate (PMMA) are often associated with macrophage 
mediated foreign body reaction and tissue fibrosis, high levels of metallic 
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particles and ions have been demonstrated to promote tissue necrosis and 
lymphocyte-driven responses (17).  
Pain is one of the clinical features observed in both AL and OA conditions (18, 
19). Innervation profile is mostly studied in the context of arthritic diseases but 
not in the presence of implantable biomaterials. Patients and animal studies 
highlighted innervation of synovial tissues as a possible player in the pain 
process and, based on anatomical mapping, suggested a coupling of 
innervation and inflammation in osteoarthritic synovial tissues (20, 21). It is 
well documented that both sympathetic, tyrosine-hydroxylase (TH)+ or 
neuropeptide Y (NPY)+, and sensory nerve fibers, substance P+ and 
calcitonin gene related peptide (CGRP)+, are present in OA synovial tissue 
and grow towards cartilage along blood vessels (21). On the other hand, so 
far, two studies addressed the innervation of the interface membranes 
surrounding AL hip prostheses (19, 22). Unfortunately, the data is still unclear. 
Niissalo et al reported that the synovial membrane-like interface did not 
contain C-sensory peptidergic or sympathetic neural structures while Ahmed 
et al identified sympathetic nerve fibers in these interface membranes (19, 
22). Thus, innervation profile and its possible association with periprosthetic 
joint inflammation, triggered by prosthetic debris in AL scenario, should be 
revised. Furthermore, the comparison of the inflammatory versus innervation 
profiles of AL and OA has never been examined and requires further 
investigation. In this study, the immune and innervation profiles of AL and OA 
were addressed dissecting local players at tissue, cellular and molecular 
levels with potential systemic translation. 
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Materials and Methods 
Patients and Samples 
Centro Hospitalar São João ethics committee approved this study and all 
patients consented to the use of their tissue and blood for research purposes. 
The followed procedures were in accordance with the Helsinki Declaration of 
1975, as revised in 2000. Samples from synovial membrane-like interface 
tissue/aseptic interface membrane were collected from twenty patients during 
hip revision surgeries due to AL of hip prostheses. All revised hips had a 
metal-on-polyethylene (MoP) coupling, eleven out twenty cemented and bone 
defects were classified according to the Paprosky classification (23). Relevant 
clinical information is summarized in Table 1. Infection, recurrent dislocation 
and periprosthetic fracture were considered exclusion criteria in the aseptic 
loosening group. Osteoarthritic synovial tissues were collected from fifteen 
patients undergoing primary hip replacement surgeries for primary OA. OA 
patients were classified for OA severity according Tönnis OA grade (24) and 
presented scores from moderate (2) to severe (3). The clinical information of 
these patients is summarized in Table 2. For both OA and AL groups, the 
same orthopedic team performed the collection of tissue samples. Previously 
to surgery, blood was collected and leukograms and plain radiographies were 
registered. 
Immediately after excision, both OA synovial tissues and aseptic interface 
tissues were split. Half of the tissue was immersed in formalin for further 
histological analysis, while dry ice was used to freeze the remaining tissue 
until storage at -80ºC. No more than 4 hours elapsed between tissue 
collection and storage. 
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Aseptic 
Loosening 
Case 
Number 
Age Gender 
Hip 
prostheses 
type 
Implant 
Fixation 
Time to 
Revision 
(months) 
Component 
Revised 
Type 
of 
bone 
defect 
Metallosis 
1 79 M MoP Cemented 13 Acetabular 2B  
2 61 F MoP Cemented 24 Acetabular 2A  
3 74 F MoP Cemented 23 Acetabular 2B  
4 86 F MoP Cemented 46 Acetabular 2B  
5 50 F MoP Uncemented 56 Acetabular 
Femoral 
3A 
1 
Yes 
6 79 F MoP Cemented 96 Acetabular 3A  
7 73 M MoP Cemented 108 Acetabular 3A  
8 69 F MoP Cemented 117 Acetabular 2C  
9 74 M MoP Cemented 120 Acetabular 
Femural 
2A 
1 
 
10 77 M MoP Uncemented 120 Acetabular 
Femoral 
2B 
1 
 
11 45 F MoP Uncemented 129 Acetabular 3A  
12 73 F MoP Uncemented 130 Acetabular 1 Yes 
13 63 F MoP Cemented 138 Acetabular 3A  
14 75 M MoP Cemented 144 Acetabular 3A  
15 62 F MoP Uncemented 153 Acetabular 2C  
16 53 F MoP Uncemented 156 Acetabular 2A  
17 86 F MoP Cemented 168 Acetabular 
Femoral 
2A 
1 
 
18 71 F MoP Uncemented 204 Acetabular 1  
19 82 F MoP Uncemented 216 Acetabular 1 Yes 
20 75 M MoP Uncemented 240 Acetabular 1 Yes 
Table 1.  Clinical data from aseptic loosening patients 
 
Osteoarthritis 
Case Number Age Gender 
OA severity 
(Tonnis 
Classification) 
1 79 F 2 
2 45 F 3 
3 54 F 3 
4 80 F 3 
5 55 M 3 
6 49 F 2 
7 76 M 3 
8 51 F 2 
9 56 F 3 
10 71 M 3 
11 74 F 3 
12 83 M 3 
13 37 F 3 
14 74 M 3 
15 66 M 2 
Table 2.  Clinical data from osteoarthritis patients 
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Histochemistry and immunostaining 
Half of collected tissues were formaldehyde-fixed paraffin embedded and 
cross-sections of 3 µm thickness were cut. Contiguous sections were stained 
with hematoxylin & eosin (H&E) and Masson’s trichrome (MT). For 
immunohistochemistry, tissue sections were deparaffinized and rehydrated 
before heat induced antigen retrieval (98ºC, 10 mM citrate buffer, pH 6.0). 
Endogenous peroxidases were blocked using 3% H2O2 and non-specific 
binding sites were blocked using Background Block (Cell Marque, USA), 
previously to the incubation with antibody diluent 1% BSA (negative control) 
or with primary antibodies: anti-CD3 (clone PS1, dilution 1:100, Biocare 
Medical, USA), anti-CD20 (clone L26, dilution 1:100, Cell Marque, USA), anti-
CD68 (clone 514H12, dilution 1:100, Novocastra, UK), anti-CD163 (clone 
MRQ-26, dilution 1:150, Cell Marque, USA), anti-HLA-DR (clone TAL1B5, 
dilution 1:5000, Abcam, USA) and anti-TGF-β1 (clone TB21, dilution 1:2000, 
Abcam, USA). After primary antibody incubation, tissue sections were 
incubated with BrightVision Poly-HRP-Anti Mouse/Rabbit/Rat IgG 
(Immunologic, the Netherlands) and then revealed using DAB Plus Substrate 
System (Thermo Scientific, USA), before hematoxylin counterstaining. The 
specificity of immunostainings of CD20, CD163, CD68, HLA-DR and CD3 was 
confirmed using human spleen as positive control.  
For immunofluorescence studies, tissue sections were deparaffinized and 
antigen retrieval of rehydrated sections was performed using Proteinase K 
(0.2 mg/mL in PBS) for NF200 immunostaining and incubated for 20 min at 
98ºC in Citrate buffer (pH 6.0), or TE Buffer (pH 9.0) for Substance P and 
CGRP staining, respectively. After quenching endogenous fluorescence with 
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0.1 % sodium borohydride and 100 mM NH4Cl, sections were incubated with 
blocking buffer (10 % FBS, 1 % BSA, 0.2 % Triton X-100). Primary antibody 
rabbit anti-human neurofilament heavy subunit (NF200) (dilution 1:1000, 
Abcam, USA), anti-Substance P (dilution 1: 1000, Millipore, USA), anti-TH 
(dilution 1:100, Millipore, USA), anti-CGRP (dilution 1:4000, Sigma-Aldrich, 
USA) or blocking buffer (negative control) was applied overnight at 4 ºC. For 
signal detection, tissue sections were incubated with anti-rabbit Alexa Fluor 
568 antibody (dilution 1:1000, Life Technologies, USA), incubated with DAPI 
and then mounted with Fluoroshield Mounting Medium (Abcam, USA). The 
specificity of immunostainings for NF200, Substance P, TH and CGRP was 
confirmed using a specimen of human Morton’s neuroma as positive control. 
 
Semi-quantitative histopathological evaluation 
In order to characterize synovial microenvironment, tissues were semi-
quantified considering the total immunoreactive area and scored into four 
categories: absent (0), present (1), frequent (2) or abundant (3), according to 
the histological grading system illustrated in the supplementary figures Figure 
S1 (tissue reaction), Figure S2 (prosthetic debris accumulation) and Figure S3 
(immune cells distribution), similarly to the methodology followed by others 
(25, 26).  
Structural changes, fibrosis and necrosis in OA synovial tissues and aseptic 
interface tissues were evaluated after H&E and MT staining. The 
thickening/hyperplasia and increased villi of synovial membrane were 
assessed in OA patients. The accumulation of polymeric, ceramic and metallic 
particles was assessed in synovial membrane-like interface tissues. A 
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polarized filter was used to detect polymeric particles. Ceramic and metallic 
particles were studied through Scanning Electron Microscopy (SEM) and their 
elemental composition assessed by Energy Dispersive Spectroscopy (EDS). 
Additionally, a phase contrast filter (Ph3) was used with an optical microscope 
to ease the detection of clusters of ceramic or metallic particles in histological 
slices, allowing a deep study of the interaction between particles and cells. 
The infiltration of target immune cell populations, identified by 
immunohistochemistry, was determined regarding the presence of 
macrophages (CD68+ cells), T cells (CD3+ cells) and B cells (CD20+ cells). 
The semi-quantification of polymorphonucleated cells (PMNs) was performed 
after PMNs identification as these cells have a lobed nucleus while 
multinucleated giant cells (GC) were detected due to their bigger size, 
multiples nucleus and CD68+ labeling.  
Tissue samples retrieved from five out thirty-five patients (4/15 OA and 1/20 
AL) were excluded from histopathological evaluation because they do not 
correspond to OA synovial tissue or aseptic interface tissue. H&E, MT and 
immunohistochemistry slices were analyzed using a light microscope 
Olympus CX31 while immunofluorescence, polarized light and phase contrast 
Ph3 images were captured on Carls Zeiss Axiovert 200 inverted microscope. 
 
Gene expression analysis 
Synovial tissues were homogenized in liquid nitrogen using a mortar and 
pestle to preserve RNA integrity. RNA was extracted and purified using TRIzol 
(Invitrogen, UK) and Direct-zol™ RNA MiniPrep (ZYMO Research, USA), 
according to the manufacturers’ instructions. The amount and quality of 
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extracted RNA were evaluated by Nanodrop ND-1000 (Thermo Fisher 
Scientific, USA) and running RNA samples in a 2% agarose gel. The 
transcriptional levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12a 
and iNOS), anti-inflammatory cytokine (IL-10), osteoclastic factor (RANKL) 
and bone remodeling factor (TGF-β1) were evaluated by quantitative real time 
PCR (qRT-PCR) in PCR iQ™5 system (Bio-rad, USA). All used primers, listed 
in Table 3, were optimized and melting curves of PCR products were 
evaluated to guarantee primers specificity. β2 microglobulin (B2M) and β-actin 
were used as reference genes. Experiments were performed in triplicated. 
Relative gene expression levels were calculated using the quantification cycle 
(Cq) method, according to MIQE guidelines (27). Fourteen out thirty-six cases 
(5/15 OA and 9/20 aseptic loosening) were excluded from gene expression 
analysis when average Cq for reference genes was above 26, to avoid bias in 
the evaluation of genes with later expression. 
 
Gene GenBank number Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
B2M [NM_004048] CCAGCGTACTCCAAAGATTCAG AGTCAACTTCAATGTCGGATGG 
β-actin [NM_001101] TACCTCATGAAGATCCTCA TTCGTGGATGCCACAGGAC 
IL-1β [NM_000576] CTTCAGCCAATCTTCATT CACTGTAATAAGCCATCAT 
IL-6 [NM_000600] CAATCTGGATTCAATGAGGAGACT CTGTTCTGGAGGTACTCTAGGTAT 
IL-10 [NM_000572] GGAGAACCTGAAGACCCTCA TATAGAGTCGCCACCCTGAT 
IL-12a [NM_000882] TACCAGGTGGAGTTCAAG GTTCTTCAAGGGAGGATTT 
iNOS [NM_000625] AATTGAATGAGGAGCAGGTC TCCTTCTTCGCCTCGTAA 
TNF-α [NM_000594] TCTCTCTAATCAGCCCTCTG TGCTACAACATGGGCTACAG 
RANKL [NM_003701] GGATGGCTCATGGTTAGA CAAGAGGACAGACTCACTT 
TGF-β1 [NM_000660] CCTGGACACCAACTATTG CTTGCGGAAGTCAATGTA 
Y1R [NM_000909] AAGAGGATTGTTCAGTTCA GATTGGTTTGGTTGTTATAGA 
Y2R [NM_000910] ACTCTTACCTATACCTTAATG GTGATTGTGGATACTTGT 
Y5R [NM_006174] AAGGAAGGGAAAGGGTGTTAC CGAGTGGCAGCAGTATTATTCT 
VMAT2 [NM_003054] TGCGGGATTCTGCATCATGT CATCCAAGAGTACCAGGGCG 
Table 3. List of primers used for quantitative qRT-PCR analysis 
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ELISA  
Serum transforming growth factor β1 (TGF-β1) concentrations were 
measured using Quantikine® ELISA Kit for human TGF-β1 (R&D Systems, 
USA), according to the manufacturer’s protocol. Cytokine concentration was 
calculated against a standard curve. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 21.0 (SPSS Inc. Chicago, IL, 
USA). The level of significance was set at p< 0.05 (*). Visual histogram 
analysis and Kolmogorov-Smirnov test were used to evaluate the normal 
distribution of continuous variables (gene expression data, TGF-β1 plasma 
concentration and percentage of immune cells in blood). Accordingly, these 
variables were analyzed using Student’s t-test or its non-parametric 
counterpart, Mann-Whitney test. Tissue immune response and innervation 
was histologically classified in different grading categories and comparisons 
between aseptic interface tissues and OA synovial were done using Chi-
square test. All graphs were prepared using Prism software (GraphPad 
software, San Diego, CA, USA). 
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Results 
Local immune responses in OA synovial tissues and synovial membrane-like 
interface tissue 
In this study, fifteen patients underwent primary hip replacement due to OA 
(Figure 1A) and twenty hip implants were revised and their acetabular defects 
classified by X-ray imaging (Figure 1B). Macroscopically, the collected 
synovial tissues at primary and revision surgeries were morphologically 
distinct. Synovial surface was white and with diffuse papillary architecture 
(dashed black line, Figure 1C and D) whereas synovial membrane-like 
interface tissues were highly fibrotic (Figure 1E) or with greyish appearance 
(Figure 1F), in case of metallosis. 
 
Figure 1. Radiological and macroscopic tissue features of OA, AL and metallosis.  
(A) Anteroposterior X-rays showing OA of the hip. (B) Failed metal-on-polyethylene total hip joint due to 
AL. (C,D) Macroscopic images of OA synovial tissue collected at primary hip replacement. (E) Synovial 
membrane-like interface tissue retrieved at hip revision surgery due to AL. (F) Metallic debris 
accumulation in synovial membrane-like tissue from AL patient with metallosis. 
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Semi-quantitative analysis of tissue organization and immune cell distribution 
in OA synovial tissue and aseptic interface tissues showed distinct local 
profiles. OA synovial membranes displayed a bicellular lining layer (LL) and a 
sublining layer (SLL) (Figure 2A) enriched in blood vessels (black arrows) and 
collagen (Figure 2B), as well as structural changes induced by synovial 
inflammation, such as synovial hyperplasia (Figure 2C and D) and increased 
number of villi (Figure 2E and F). OA patients presented at least one sign of 
synovial inflammation (thickening or villi) but their magnitude was variable 
among patients (Figure 2C and E). Synovial membrane-like interface tissues 
presented fibrotic stroma with increased collagen deposition (Figure 2G and 
H) than OA synovial tissues (p=0.001) and with some necrotic regions (Figure 
2I). 
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Figure 2. Histological evaluation of tissues organization 
(A) OA synovial tissue is composed by different cell types and matrixes organized in synovial lining 
layer (LL) and sublining layer (SLL). (B) Dense net of blood vessels (black arrows) was found in SLL 
together with loose connective tissue (blue stain). (C) Histological grading for synovial membrane 
thickening in OA. (D) Synovial membrane thickening (ST) with reactive neo vascularization. (E) 
Histological grading for synovial villous expansion in OA. (F) OA synovial membrane presenting villous 
hypertrophy (SV). (G) Histological grading for tissue fibrosis. (H) Synovial membrane-like interface 
tissue showing fibrosis characterized by intense deposition of collagen fibers (blue stain). (I) Histological 
grading for tissue necrosis. Masson’s trichrome (A,B,D,F,H) staining. Scale bars correspond to 500 µm 
(B,F,H), 200 µm (D) and 50 µm (A). Semi-quantitative histological evaluation of tissue architecture was 
performed in specimens retrieved from 11/15 OA and 19/20 AL patients. *** p<0.001. Chi-square test 
was used to compare OA and AL groups. 
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The accumulation of prosthetic debris in synovial membrane-like interface 
tissues was semi-quantified. Polymeric particles were just detected in 11/20 
analyzed aseptic interface tissues (Figure 3A) after tissue analysis under 
polarized light (Figure 3B and C). No significant difference was found between 
AL patients with cemented and uncemented MoP bearings regarding the 
amount of polymeric particles entrapped in synovial membrane-like tissues. 
Zirconia particles (ZrO2) were observed in almost all synovial membrane-like 
interface tissues retrieved from patients with loose cemented prostheses 
(Figure 3D-F) and mainly phagocytized by macrophages or multinucleated 
giant cells (Figure 3G). Ph3 contrast filter eased the detection of ZrO2 
particles (Figure 3E and F). White color particles under Ph3 filter were 
confirmed to be ZrO2 and to be organized in clusters of nanoparticles by 
SEM/EDS (Figure 3H and I). Intense deposition of metallic particles was just 
found in the four cases of metallosis that were patients with uncemented 
metal-back acetabular cups (Figure 3J). Aseptic interface membranes with 
metallosis presented high deposition of metallic particles with concomitant 
macrophage infiltration (Figure 3K), tissue fibrosis (Figure 3L) and necrosis 
(Figure 3M). Under Ph3 filter, metallic nanoparticles and haemoglobin 
presented violet and red color respectively, which allow distinguishing them 
from ZrO2 particles (Figure 3N and O). 
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Figure 3. Prosthetic debris accumulation in synovial membrane-like tissues 
(A) Histological grading for accumulation of polymeric particles (PP) in aseptic interface membranes. (B) 
PP surrounded by macrophages (brown cells). (C) Same section of (H) under polarized light showing 
birefringent PP. (D) Histological grading for deposition of ZrO2 particles in synovial membrane-like 
interface tissues. (E) H&E image of aseptic interface membrane with intense deposition of ZrO2 particles 
(black arrows) using conventional light microscopy. (F) Same tissue region observed using Ph3 filter 
with white and bright particles corresponding to ZrO2 debris (white arrows). (G) Macrophages (brown 
cells) phagocytizing ZrO2 debris (black arrows). (H) SEM image of synovial membrane-like interface 
tissues containing clusters (Z1) and sole (Z2) ZrO2 nanoparticles. (I) EDS analysis confirming the 
elemental composition of ZrO2 nanoparticles. (J) Histological grading for entrapment of metallic particles 
in tissues. (K) Macrophages (brown cells, CD68+ cells) with phagocytized metallic particles. (L) Metallic 
particles co-localized with macrophages and high deposition of collagen (blue stain). (M) Necrosis (N) in 
regions of aseptic interface membranes with massive accumulation of metallic particles. (N) Tissue from 
an AL patient with metallosis showing metallic particles and erythrocytes. (O) Same tissue section 
shwoing bright metallic particles and erythrocytes but exhibited under Ph3 filter violet and red colors, 
respectively. H&E staining (E,M,N), polarized light (C), Ph3 filter (F,O), Masson’s trichrome (L) 
immunohistochemistry (B,G,K), SEM imaging (H) and EDS spectra (I). Scale bars correspond to 500 µm 
(E,M), 50 µm (B,K,L) and 20 µm (G,N,O). Semi-quantitative histological evaluation was performed in 
tissues retrieved from 19/20 AL patients. 
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Immune cell distribution was studied in tissues from AL and OA patients. In 
AL, macrophages (CD68+ cells) were more abundant than in AL (p=0.007; 
Figure 4A), often confined to lining layer in OA patients (Figure 4B), while 
significant macrophage infiltration was found in synovial membrane-like 
interface tissues (Figure 4C). In these tissues, co-localization between 
polymeric particles and macrophages was often found (Figure 4D) and a 
similar pattern was observed in AL patients with cemented and uncemented 
MoP bearings. In AL patients, macrophages were the most prevalent immune 
cell population, even in metallosis cases, and in overall highly express M1 
(HLA-DR; Figure 4E) and M2 (CD163; Figure 4F) markers. Multinucleated 
giant cells in foreign body reaction setting were mostly found in synovial 
membrane-like interface tissues (p=0.037, Figure 4G) surrounding big 
polymeric particles, likely PMMA, with ZrO2 particles entrapped inside (Figure 
4H). T cells (CD3+ cells) (Figure 4J), and B cells (CD20+ cells; Figure 4L) in 
lower number, could be detected in the majority of tissues collected from AL 
and OA patients (Figure 4I and K), including AL patients with uncemented 
implants or signs of metallosis. Moreover, the number of PMNs was also low 
in both aseptic interface membranes and OA synovial tissues (Figure 4M and 
N). Overall, the immune cell populations addressed, namely macrophages, T 
cells, B cells and PMNs, in this study were most located in the vicinity of 
synovial membrane in OA patients, while in AL patients these cells were 
identified throughout the aseptic interface membranes. 
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Figure 4. Immune cells distribution in OA synovial tissues and aseptic interface membranes 
(A) Histological grading for macrophage (CD68+ cells) infiltration in tissues. (B) In OA, macrophages 
(brown cells) were almost found at LL. (C) Intense macrophage (brown cells) infiltration was detected in 
synovial membrane-like interface tissues. (D) In aseptic interface tissues, macrophages (brown cells) 
were often found surrounding or phagocytizing prosthetic debris such as polymeric particles (PP) and 
ZrO2 particles (black arrows). (E) HLA-DR+ cells – an M1 macrophage marker. (F) CD163+ cells – an 
M2 macrophage marker. (G) Histological grading for multinucleated giant cells in tissues  (H) 
Multinucleated giant cells (GC) phagocyting a big PP particle with ZrO2 particles (black arrows) 
entrapped inside. (I) Histological grading for T cells (CD3+ cells). (J) Perivascular T cells (brown cells) 
clusters in OA synovial tissue. (K) Histological grading for B cells (CD20+ cells). (L) B cells (brown cells) 
in lymphocyte aggregates around blood vessels but in lower number than T cells. (M) Histological 
grading for polymorphonucleated cells (PMNs). (N) Increased number of PMNs (black arrows) in 
synovial membrane-like tissue with macrophages (brown cells, CD68+ cells). Masson’s trichrome 
staining (H) and immunohistochemistry (B,C,D,E,F,J,L,N). Scale bars correspond to 500 µm (B,C) and 
50 µm (D,E,F,H,J,L,N). Semi-quantitative histological evaluation was performed in synovial tissues 
retrieved from 11/15 OA and 19/20 AL patients. * p<0.05, *** p<0.001. Chi-square test was used to 
compare OA and AL groups. 
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Local innervation in AL and OA patients 
Myelinated nerve fibers identified by NF200 immunoreactivity were detected 
in both synovial membrane-like interface tissues and OA synovial tissues. 
They were presented as single fibers (Figure 5A and C) and were 
preferentially arranged around blood vessels (Figure 5C) particularly in tissue 
regions of reactive vascularization induced by immune responses underlying 
AL and OA. Alternatively, nerve fibers were also found in neurome-like 
structures (Figure 5B and D) in both AL and OA patients. Sensory and 
sympathetic innervation, as seen by immunohistochemical markers of sensory 
nerve-associated peptides (Substance P and CGRP) and catecholaminergic 
marker of sympathetic neurons (TH), showed different pattern between OA 
patients and AL patients. TH immunoreactive nerve fibers were observed in 
OA synovial tissues (Figure 5F) but not in synovial membrane-like interface 
tissues (Figure 5G and H). Substance P and CGRP were found both in OA 
synovial tissues and synovial membrane-like interface tissues but showed 
different pattern. In OA synovial tissues, nerve fibers immunoreactive to 
Substance P and SGRP were observed mainly around blood vessels in the 
vicinity of synovial membrane (Figure 5J and N). In addition, a high number of 
cells in the OA synovial membrane also stained for TH, Substance P and 
CGRP (Figure 5E, I and M). In synovial membrane-like interface tissues, the 
expression of Substance P and CGRP was also found in both nerve fibers 
and cells but with a broad distribution throughout the tissue (Figure 5K, L, O 
and P). 
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Figure 5. Local tissue innervation in OA and AL patients 
(A-D) NF200+ fibers (red) as sole fiber or organized in neurome-like structures in OA synovial tissues as 
well as in aseptic interface membranes. (E) Synovial cells expressing TH (red). (F) TH+ fiber surround a 
blood vessel. (G,H) Nor fibrotic nor reactive tisue with giant cells presented positive labelling for TH. (I) 
Substance P+ cells in OA synovium membrane. (J) Substance P+ fibers and cells surrounding a blood 
vessel located at subintimia of OA synovial tissue. (K,L) In AL patients, Substance P+ fibers were just 
found in fibrotic regions. (M) CGRP+ cells in synovial membrane. (N) CGRP+ fibers along a blood 
vessel in OA synovial tissue. (O,P) Some cells expressing CGRP in aspetic interface tissue. 
red=NF200+ or TH+ or Substance P+ or CGRP+, blue=cell nuclei, green=autofluorescence) Scale bars 
correspond to 50 µm (A, B, D, F, G, H, I, J, K, L, M, N, O, P) and 200 µm (E). 100 µm (C). 
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Local gene expression profile 
The expression levels of pro-inflammatory cytokines tumor necrosis factor-α 
(TNF-α), interleukin-1β (IL-1β) and IL-6 were similar in aseptic interface 
tissues and OA synovial tissues (Figure 6A-C). Inducible nitric oxide synthase 
(iNOS) and IL-12a expression levels were found to be low when compared 
with the TNF-α, IL-1β and IL-6 mRNA levels detected in AL and OA groups 
(Figure 6D and E). Interestingly, the anti-inflammatory cytokine IL-10 
presented a tendency (p=0.084) to be higher expressed in synovial 
membrane-like tissues than in OA synovial tissues (Figure 6F). Two genes 
involved in bone remodeling were evaluated: TGF-β1 and receptor activator 
of nuclear factor kappa-B ligand (RANKL). The mRNA levels of TGF-β1 were 
significantly reduced (p=0.038) in aseptic interface tissues when compared to 
OA synovial tissues (Figure 6G). However, no differences between AL and 
OA patients were verified for RANKL (Figure 6H) and no correlation was 
found between mRNA levels of RANKL and the bone defect type. 
 
Figure 6. Gene expression profiles of cytokines in aseptic interface membrane and OA synovial 
tissues 
Relative expression levels of genes of interest determined through qRT-PCR and normalized by two 
reference genes, β-actin and B2M: (A) IL-1β, (B) TNF-α, (C) IL-6, (D) iNOS, (E) IL-12a, (F) IL-10, (G) 
TGF-β1 and (H) RANKL. Data of 10/15 OA patients and 11/20 AL patients are shown. Significant 
difference of TGF-β1 expression between AL and OA groups (*p < 0.05). Mann-Whitney test was 
utilized to compare and analyze the obtainded data. 
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Local production of TGF-β1 
In both AL and OA patients, TGF-β1 was detected in blood vessels 
endothelium cells (Figure 7A), macrophages (Figure 7B) and fibroblasts 
(Figure 7C). Interestingly, differences in the pattern of TGF-β1 expression 
were found between AL patients and OA. Aseptic interface tissues presented 
a trend (p=0.1672) toward increased number of regions expressing TGF-β1 
(Figure 7D). In OA synovial tissues, TGF-β1 was present in the sublining layer 
of synovial membrane (Figure 7E), in aggregates of lymphocytes (Figure 7F) 
and blood vessels. In synovial membrane-like interface tissues, the 
distribution of TGF-β1-positive regions was heterogeneous (Figure 7G and 
H). 
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Figure 7. TGF-β1 expression in synovial membrane-like interface tissues and OA synovial 
tissues 
(A) TGF-β1+ endothelial cells in aseptic interface tissue with metallosis. (B) TGF-β1+ macrophages in 
synovial membrane-like interface tissue. (C) TGF-β1+ fibroblast in aseptic interface membrane. (D) 
Number of OA and AL patients classified with score from 0 to 3 regarding the presence of TGF-β1 in 
tissue. (E) OA synovial membrane with positive labelling at sublining layer and endotethelium (black 
arrows). (F) Lymphocyte aggregate in OA synovial tissue with positive cells for TGF-β1. (G) Aseptic 
interface membrane presenting heterogenous TGF-β1 labelling. (H) Multinucleated giant cell (GC) 
phagocyting a polymeric particle (PP) with ZrO2 particles inside (black clusters) with TGF-β1+ 
endothelial cells in the vicinity. Scale bars correspond to 500 µm (G) and 50 µm (A,B,C,E,F,H). Data 
was collected for 11/15 OA patients and for 19/20 AL patients. Chi-square test was used to compare OA 
and AL groups. 
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Immune cells proportions and TGF-β1 concentration in blood 
The preoperative leukograms were analyzed and the concentration of TGF-β1 
determined in plasma of both AL and OA patients. The percentage of 
circulating monocytes in both groups tended to be similar (Figure 8A). 
Interestingly, the percentage of lymphocytes seemed to be low in AL patients 
but within the reference interval in OA group (Figure 8B). Neutrophils did not 
present significant alterations compared with the reference values (Figure 
8C). Remarkably, the levels of TGF-β1 in serum were similar in both groups 
(Figure 8D). 
 
 
Figure 8 - Pre-operative evaluation of immune populations and TGF-β1 in blood 
Data regarding the percentage of the following immune population in leukocytes count. (A) Monocytes. 
(B) Lymphocytes. (C) Neutrophils. Data was collected for 14/15 OA patients and for 17/20 AL patients. 
Dashed lines represent minimum and maximum reference values. (D) TGF-β1 serum concentration was 
determined for 13/15 OA patients and for all 20 AL patients. 
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Discussion 
AL and OA differences rely on tissue architecture, immune cell distribution, 
local TGF-β1 expression as well as sensory and sympathetic synovial 
innervation. On the other hand, both pathologies share identical inflammatory 
mediators mRNA profiles and similar TGF-β1 concentrations in serum, as 
summarized in Figure 9. 
 
Figure 9. Overview of hip microenvironment in OA and AL 
 
Chapter	III	–	Immune	response	and	innervation	signatures	in	aseptic	hip	implant	loosening	
	
	 124	
Synovial membrane-like interface tissues, present in the vicinity of loose 
prostheses, showed a macrophage-driven chronic inflammation. This immune 
response is likely influenced by both OA inflammatory background and the 
presence of prosthetic debris, leading to significant changes of local TGF-β1 
expression but not systemically. 
Distinct tissue organization and immune cell distribution were found in the 
tissues retrieved from the hip joint of AL and OA patients. OA synovial tissues 
presented signs of synovial inflammation (synovitis), such as synovial 
hyperplasia and villous hypertrophy, while aseptic interface membranes, 
formed after primary hip replacement, exhibited a particle-driven chronic 
inflammation. Intense infiltration of macrophages (CD68+ cells) was observed 
in AL patients in comparison to OA synovial tissues. In synovial membrane-
like interface tissues retrieved from AL patients, macrophages were the 
predominant immune cell type and were involved in the phagocytosis of small 
particles (< 10µm) or encapsulating bigger polymeric particles as 
multinucleated giant cells, in line with previous works about the role of 
macrophages on AL (28). Although PE particles, released by MoP 
prostheses, have been pointed out as AL catalyzers (29, 30), other types of 
particles may play a role on the pro-inflammatory microenvironment 
underlying osteolysis. Large amounts of metallic particles were observed in 
four out nine AL patients due to impingement of metallic components of 
uncemented MoP bearings. 
Ceramic ZrO2 particles, incorporated in bone cements for implants fixation as 
radiopacifier agent, were found in synovial membrane-like interface tissues 
from all the patients with cemented prostheses. Light microscopy with Ph3 
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contrast filter and SEM/EDS analysis revealed that ZrO2 gradually migrate 
from cement particles (PMMA) to other regions of aseptic interface tissues in 
high number, namely after being phagocytized by macrophages. ZrO2 
particles were shown to be moderately toxic, activate macrophages, promote 
the expression of pro-inflammatory cytokines (TNF-α) and induce osteolysis in 
vivo (31, 32). Despite reported not toxic as metallic particles or studied as 
polymeric debris (12, 33, 34), ZrO2 particles should not be neglected, as they 
are numerous, common and nano-sized with potential to unbalance 
inflammation towards osteolysis. It has been reported that particle-induced 
response is prone to drive macrophages towards M1 phenotype and that 
M1:M2 ratio was higher in synovial membrane-like interface tissue than in OA 
synovial tissues (35, 36). However, macrophage polarization in joint tissues 
remains controversial. In this study, the density of polymeric, metallic or ZrO2 
particles on aseptic interface tissues did not lead to local preferential 
macrophage polarization in M1 pro-inflammatory (HLA-DR+) or M2 pro-
regenerative phenotypes (CD163+) as both receptors were similarly 
expressed on macrophages. In addition to the involvement of macrophages 
and lymphocytes in local inflammatory response, preoperative leukograms 
suggested monocyte expansion and contraction of lymphoid population in AL 
group. 
Cytokines expression profile was found similar in synovial membrane-like 
interface tissues and OA synovial tissues, despite their distinct tissue 
architecture and immune cell distribution. The response of macrophages to 
prosthetic debris is believed to induce the production of the pro-inflammatory 
markers such as TNF-α, IL-1β, IL-6, IL-12a, and iNOS (28, 34, 37). However 
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those genes revealed similar mRNA levels in AL and OA patients, which is in 
line with comparable studies (26, 30, 38). The changes in cytokine expression 
induced by AL seem to be controversial (25). Reduced mRNA levels of IL-6 
have also been described in aseptic interface membranes (26) while IL-6 was 
found significantly increase in synovial fluid of AL patients (25, 30). A trend for 
higher mRNA levels of the anti-inflammatory cytokine IL-10 was observed in 
synovial membrane-like interface tissues in comparison to OA synovial 
tissues (p=0.084). This result corroborates with other findings showing 
significant increase of IL10 protein levels in synovial fluid and interface tissues 
of AL patients (25, 26, 30). The up-regulation of IL-10 in aseptic interface 
tissues may constitute an attempt to balance the pro-inflammatory 
microenvironment induced by prosthetic debris (39, 40).  
Although RANKL is involved in osteoclastogenesis and osteolysis, similar 
mRNA levels were found in AL and OA patients, in agreement with other 
authors (26, 30, 38, 41). In overall, identical pattern regarding the expression 
of cytokines was found in AL and OA patients. In the context of AL, no 
significant differences were registered between polyethylene-drive and 
metallosis cases as previously shown (42). The expression of TGF-β1 mRNA 
in synovial membrane-like interface tissues was found significantly lower than 
in OA synovial tissues but local TGF-β1 immunostaining suggested increased 
expression of this protein in AL patients in comparison to OA patients. These 
findings corroborate the results presented by other authors that have also 
found increased TGF-β1 mRNA levels in OA cartilage (9, 43, 44) and 
augmented TGF-β1 expression in synovial membrane-like interface tissues 
(45). In both AL and OA, TGF-β1+ labeling was prominent in sites where the 
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inflammation is occurring and mostly expressed in macrophages, fibroblasts 
and endothelium cells. However, while in OA the TGF-β1+ cells were found in 
the region of synovial membrane, in AL, the distribution was more 
heterogeneous and throughout different tissue regions. These results suggest 
a possible association between TGF-β1 and the immune responses that 
underlie AL and OA. Despite a previous report indicates that in OA 
pathogenesis, TGF-β1 might have a pro-inflammatory effect by inducing 
fibroblasts to express TNF-α and IL-1β (46), its involvement in inflammatory 
response is not fully understood. Although the involvement of TGF-β1 in 
fibrosis is widely described, this growth factor may have dual effects on 
arthritic diseases (47). Both immune cells and fibroblasts are part of the 
complex microenvironments that underlie AL and OA and in which TGF-β1 
may have different effects depending on levels of other inflammatory 
mediators. Additionally, in the context of particle-induced immune response, 
TGF-β1 has a conjoint role with other factors on bone remodeling (12).  
Moreover, previous studies demonstrated that serum TGF-β1 has not 
predictive value to assess OA incidence and progression (48, 49). In our 
study, despite the difference in tissues regarding TGF-β1, AL and OA patients 
presented similar concentrations of TGF-β1 in serum.  
The crosstalk between inflammation and innervation has been widely 
investigated in several joint-related disorders but not in presence of 
prostheses (50, 51). Previous studies have reported sensory and sympathetic 
innervation in joints diseases namely OA and rheumatoid arthritis (RA), where 
an inflammatory response is taken place within synovial tissues or in the 
vicinity of the articulation. Our study demonstrated for the first time distinct 
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pattern of sensory and sympathetic innervation in AL patients characterized 
by a loss of sympathetic nerve fibers when compared to OA patients. This 
differential profile has been also described in a comparative study showing 
lack of sympathetic innervation in RA patients while in OA patients this does 
not occur (52). The authors suggested that the reduction or absence of 
sympathetic innervation might be a consequence of the initial synovial 
inflammation, probably involving nerve repellent molecules (53), and a key 
factor to its maintenance in RA. In AL, a sustained chronic inflammatory 
response is maintained by the presence of prosthetic debris, primarily 
generated at the bearing surface of hip prostheses. Therefore, our findings, 
supported by those described in RA, strongly indicate a close correlation 
between sympathetic innervation pattern and the degree of the inflammatory 
response. A previous study described the appearance of TH+ cells in the 
collagen-induced arthritis in mice and hypothesized that the presence of those 
cells might be a compensatory mechanism to the deprivation of sympathetic 
neurotransmitters in the joint (54). In AL patients, TH+ catecholamine-
producing cells were not detected in the synovial membrane-like interface, 
suggesting total uncoupling of local joint inflammation from the sympathetic 
activity (nerve fibers and cells).  
Several animal and human studies have addressed the pattern of the sensory 
innervation in arthritis, namely in OA, and reported a significant re-
organization of the sensory nerve fibers characterized by an alteration in the 
morphology, density and sprouting into areas of the joint that are normally 
poorly innervated (21). In this study, we showed that there is also alteration in 
the sensorial innervation of synovial membrane-like interface tissues in AL 
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patients with a notable distinct tissue distribution when compared to OA. 
Substance P and CGRP immunoreactive nerve fibers were observed in 
subintima regions (outer layer) mainly around blood vessels while in AL they 
were distributed throughout synovial membrane-like interface tissues. Of note, 
Substance P+ and CGRP+ cells were also found in these tissues as an 
additional source of these neuropeptides. Although, Substance P and CGRP 
are recognized as neuro-inflammatory modulators in arthritic joints, their 
functional role in the inflammatory response associated to prosthetic debris as 
well as in the reorganization of sensory and sympathetic nerve fibers in 
inflamed joint need to be clarified. 
We acknowledge certain limitations in this study. To study the differences 
between AL and OA, thirty five patients were included in our study, an 
average number in the field (40). OA synovial tissues and synovial 
membrane-like interface tissues were retrieved by the same surgeon to 
minimize location bias. The histological semi-quantification of accumulation of 
prosthetic debris in aseptic interface tissues was limited to micro-sized 
particles, or clusters of nanoparticles, although tissues have been previously 
evaluated by SEM. Gene expression analysis was successfully performed in 
eleven out of twenty AL patients due to low RNA quality. Patients’ stratification 
concerning implant fixation and metallosis (AL group) or disease severity (OA 
group) was performed but no significant effect was identified. On the other 
hand, the interpretation of the variability between patients may not be just 
influenced by a specific biological response in joint region but by other factors 
such as patients comorbidities (e.g. diabetes mellitus and dyslipidemia), 
geriatric condition, or genetic susceptibility to AL (16, 55).  
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Conclusion 
Overall this study showed that AL and OA are two joint pathologies 
characterized by local immune response however with distinct tissue 
organization and immune cell distribution. This differential immune profile is 
also accompanied with changes of sensory and sympathetic innervation in hip 
joint. These findings highlight that the interplay between inflammation and 
innervation may be joint pathology-specific. Therefore, a deeper and conjoint 
understanding of these processes will constitute a solid base for targeted-
therapies to improve hip joint lifetime and treatment. 
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Figure S1. Histological grading applied in semi-quantification of OA synovial tissues 
inflammation and tissue fibrosis, necrosis, innervation (NF200) and TGF-β1 in tissues collected 
from OA and AL patients 
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Additional File 2 
 
 
	
Figure S2. Histological grading applied in semi-quantification regarding the accumulation of 
prosthetic debris in synovial membrane-like interface tissues 
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Additional File 3 
 
 
	
Figure S3. Histological grading applied in semi-quantification of immune cells prevalence and 
distribution in tissues retrieved from OA and AL patients 
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Abstract  
Inflammation is a common symptom in joint disorders such as rheumatoid 
arthritis, osteoarthritis (OA) and implant aseptic loosening (AL). The 
sympathetic nervous system is well known to play a critical role in regulating 
inflammatory conditions, and imbalanced sympathetic signaling has been 
observed in rheumatoid arthritis. In AL it is not clear whether the sympathetic 
signaling is impacted. In this study we evaluated the systemic and local profile 
of neuroimmune molecules involved in the interplay between the sympathetic 
nervous system and the periprosthetic inflammation in hip AL. Our results 
showed that periprosthetic inflammation does not trigger a systemic response 
of the sympathetic nervous system, but is mirrored rather by the impairment of 
the sympathetic signaling locally in the hip joint. Macrophages were identified 
as key players in the local regulation of inflammation by the sympathetic 
nervous system in a process that is implant debris-dependent and entails the 
reduction of both adrenergic and Neuropetide Y (NPY)-ergic signaling. 
Additionally, our results showed a downregulation of semaphorin 3A 
(SEMA3A) that may be part of the mechanism sustaining the periprosthetic 
inflammation. Overall, the local sympathetic signaling emerges as a putative 
target to mitigate the inflammatory response to debris release and extending 
the lifespan of orthopedic implants. 
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Introduction 
Osteoarthritis (OA) is one of the most prevalent chronic joint diseases and a 
major contributor to functional disability and loss of autonomy in older adults 
(1). It is associated with a substantial economic and social burden, which will 
be even higher in the upcoming years, with the expect aging of the population 
(1). Total joint replacement is considered the actual goal standard for the 
treatment of patients with severe osteoarthritis, providing pain relieve, 
improving joint function and enhancing patients´ quality of life (2, 3). 
Unfortunately, total joint replacements can end up failing, mostly due to 
periprosthetic inflammation featured by sustained chronic inflammatory 
response initiated by implant degradation products that shed and accumulate 
in the neighbor tissue (4). This adverse tissue reaction is orchestrated by the 
large plethora of immune cells of which the macrophage lineage has been 
shown to be of major relevance (4, 5). It is well established that macrophages 
differentiation towards M1 (pro-inflammatory) or M2 (anti-inflammatory) 
phenotype is of major relevance to the inflammation state and/or resolution. In 
vitro studies have shown that Polymethyl methacrylate (PMMA) and ultra-high 
molecular weight polyethylene (UHMWPE) implant particles can polarize 
macrophages to pro-inflammatory M1 phenotype (6-8). The activation of 
macrophages and other local cells results in the release of pro-inflammatory 
factors such as cytokines, chemokines, prostanoids, degradative enzymes 
and reactive oxygen species (5, 9). These factors underlie the chronic 
inflammatory scenario that may lead to painful synovitis, pathologic fracture of 
the surrounding bone and impaired function, instability and loosening of the 
implant (9). 
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Over the past decades, accumulated evidence has clearly attributed a pivotal 
role to the sympathetic nervous system and its neurotransmitters in the 
regulation of chronic inflammatory conditions (10, 11). It has been 
demonstrated that the activation of the sympathetic nervous system in the 
context of inflammation results in the release of high amounts of sympathetic 
neurotransmitters known to induce an anti-inflammatory effect in a context-
dependent manner (11, 12). The immunomodulatory effect of sympathetic 
nervous system can be achieved directly via adrenergic receptors (ADRs) 
expressed by the immune cells. Two types of ADRs have been characterized, 
the alpha (A) and beta (B), which were further divided into nine receptors 
subtypes (A1A, A1B, A1D, A2A, A2B, A2C, B1, B2 and B3)(13). Stimulation of 
ADRB2 is reported to activate anti-inflammatory mechanisms on immune 
cells, while stimuli via ADRA activates pro-inflammatory mechanisms (14). 
Therefore, the overall result will depend on the ADRs family being activated, 
which in turn depends on the receptors expression profile, and also on the 
norepinephrine concentration because norepinephrine has a high affinity to 
ADRA, only binding to ADRB when at high concentrations (14). 
The neuropeptide y (NPY), is a neurotransmitters co-released with 
norepinephrine by the sympathetic nerve fibers that has also been reported to 
have modulatory effects on the immune cells activity (15). On the context of 
the immune response, of the five NPY receptors, the Y1 receptor (Y1R) is the 
most well studied, and has been shown to have a critical role in 
immunomodulation, as demonstrated for example by the attenuation of 
inflammation in Y1R knockout mice (16). In healthy human joints, the 
synovium is richly innervated with both sympathetic and sensory nerve fibers 
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(17). In rheumatoid arthritis, data obtained in humans and in animal models 
revealed a deprivation of neuronal derived neurotransmitters in synovium 
tissue, due to the loss of sympathetic innervation (14, 18-20). Moreover, the 
extent of this deprivation is correlated with the severity of the inflammation. In 
fact, comparative studies reported a reduction of sympathetic innervation in 
synovial tissue of rheumatoid arthritis patients while in OA patients this does 
not occur (18). In our previous work, we reported similar absence of 
sympathetic nerve fibers in periprosthetic tissues from AL patients while, 
again, in OA patients this does not occur (21). In view of this evidence, the 
sympathetic activity is affected by the intensity of inflammation taking place in 
the joint.  
However, it is still unknown whether in periprosthetic inflammation associated 
to the release of debris from orthopedic implants occurs a complete shutdown 
of the sympathetic activity without any rescue mechanisms, and if the 
observed alterations are restricted to the joint or are also reflected at systemic 
level. 
In this study we evaluated the systemic and the local profile of neuroimmune 
molecules involved in the interplay between sympathetic nervous system and 
the inflammatory response to the debris released by hip implants in AL. A 
comparison with OA was performed.  
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Results 
Periprosthetic inflammation does not trigger the activation of the systemic 
neuroimmune regulatory pathway 
Several studies have shown the activation of the systemic sympathetic 
nervous system in response to pro-inflammatory cytokines as a means to 
mobilize energy-rich molecules and sustain the inflammatory process (14). In 
order to investigate the impact of periprosthetic inflammation on the systemic 
sympathetic nervous system activity, the serum levels of norepinephrine, 
epinephrine and NPY (markers of sympathetic nervous system activity) were 
measured in AL patients, OA patients and healthy donors. In addition, the 
serum levels of cortisol were also assessed in the same groups as an 
indicator of the Hypothalamus-Pituitary-Adrenal (HPA) axis activity, a system 
that together with sympathetic nervous system compose the hormonal 
pathway through which the central nervous system exerts a regulatory 
control over inflammation (14). No differences were found in the 
norepinephrine and NPY serum levels between the three groups (Figure 1a). 
Epinephrine levels were below the detection limit of the used commercial kit. 
A trend to higher cortisol levels was observed in AL patients when compared 
with healthy donors (p=0.0658), although no statistically significant 
differences were found (Figure 1a).  
The serum levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, 
key players in the activation of the sympathetic nervous system and HPA 
axis in response to inflammation (14), were also measured in AL and OA 
patients and in healthy donors. The blood levels of IL-6 were higher in AL 
and OA patients as compared to healthy donors (p<0.001 and p<0.01, 
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respectively) (Figure 1b). The levels of IL-1β and TNF-α were observed to be 
below the ELISA kits’ detection limits in all groups.  
Normal cortisol serum levels in the presence of high IL-6 concentrations are 
indicative of an inadequate cortisol secretion (22), and the ratio serum 
cortisol/IL-6 was shown to be the more suitable indicator of the HPA axis 
activity (23). Therefore, to further evaluate the HPA axis activity the ratio of 
serum cortisol / IL-6 was calculated. Results showed no differences in this 
ratio between the groups, although a not statistically significant trend to lower 
values was observed in AO patients when compared with healthy donors 
(p=0.0517) (Figure 1c).  
 
Figure 1. The systemic neuroimmune regulatory pathway was not targeted by periprosthetic 
inflammation in AL patients 
The levels of norepinephrine, NPY and cortisol (a) and the levels of IL-6 (b) were evaluated by ELISA in 
the serum collected pre-operatively from OA and AL patients, and from healthy donors. The ratio serum 
cortisol/IL-6 was calculated (c). Results are presented as mean ± SEM, n= 13-15 for healthy donors and 
AO patients and n=14-20 for AL patients. ** p< 0.01; **** p< 0.001. 
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Local sympathetic signaling is impaired in macrophages in periprosthetic 
tissues from AL patients  
Locally, the sympathetic nervous system is known to modulate the 
inflammatory response throughout adrenergic and NPY-ergic signaling (14). 
In order to explore the effect of the sustained release of debris from implants 
on the local sympathetic immune-regulation the expression of tyrosine 
hydroxylase (TH), ADRA1, ADRA2A and ADRB2, as well as of NPY and 
Y1R by macrophages, B and T cells (immune cells previously identified, in 
the same samples used in the present study, as the most prevalent in 
periprosthetic tissues and in OA synovial membrane (21)) was analyzed in 
periprosthetic tissues and compared with OA synovial tissues. Macrophages 
in OA synovial tissues were found to express TH, ADRA1 and ADRB2, but 
not the macrophages present in periprosthetic tissues (Figure 2a). ADRA2A 
was expressed by macrophages in both tissues (Figure 2a). Macrophages in 
OA synovial tissues also stained positively for NPY but not macrophages in 
AL tissues (Figure 2b).  
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Figure 2. Macrophages in Al periprosthetic tissues do not express TH or ADRB2 
The expression of TH, ADRA1, ADRA2A and ADRB2 (a) and the expression of NPY and Y1R (b) by 
macrophages (CD68+) was evaluated in periprosthetic tissues from AL patients and in synovial tissues 
from OA patients through double immunohistochemistry staining. Macrophages expressing TH, ADRA1, 
ADRA2A, ADRB2 or NPY are highlighted with triangle head white arrows. Simple head white arrows 
indicate macrophages and white arrowheads highlight TH, ADRA1, ADRB2, NPY and Y1R staining in 
cells other than macrophages (positive control). Scale bar= 20 µm. 
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Interestingly, the activation of ADRB2 in macrophages has been shown to 
promote a preferential differentiation of macrophages towards anti-
inflammatory M2 phenotype over the pro-inflammatory M1 phenotype (24). 
However, to our knowledge, the expression profile of ADRB2 in M1 and M2 
macrophages was never described. Here we show that in vitro macrophages 
display a lower ADRB2 mRNA expression levels in M1 as compared to M2 
phenotypes (p<0.05) (Figure 3). The in vitro analysis of ADRA1 and ADRA2 
mRNA expression in M1 and M2 macrophages showed very low expression 
values, which were in some samples even bellow the detection limit. Still, 
from the results we were able to achieve, no differences were found in the 
ADRA1 and ADRA2 mRNA expression between M1 and M2 macrophages 
(data not shown). 
 
 
Figure 3. The in vitro expression of ADRB2 is lower in M1 as compared with M2 macrophages 
The in vitro mRNA expression of ADRB2 was evaluated in Mo, M1 and M2 macrophages phenotypes. 
Results are represented as mean ± SEM, for n=5 per group. Each symbol represents macrophages 
obtained from one specific blood donor. * p< 0.05. 
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T cells were found to express ADRA1 both in periprosthetic tissues and OA 
synovial membrane, but not ADRA2A and ADRB2 (Figure 4a). T cells were 
also expressing TH in OA but not in AL tissues. B cells were not expressing 
the adrenergic markers investigated neither in AL nor in OA (Figure 5a) and 
the expression of NPY and Y1R was absent from T and B cells in both 
pathologic conditions (Figure 4b and 5b). 
 
  
Figure 4. T cells express ADRA1 both in 
AL periprosthetic tissues and OA 
synovial membrane 
The expression of TH, ADRA1, ADRA2A 
and ADRB2 (a), and the expression of NPY 
and Y1R (b) in T cells (CD3+) was 
evaluated in periprosthetic tissues from AL 
patients and in synovial tissues from OA 
patients through a double 
immunohistochemistry staining. T cells 
expressing TH or ADRA1 are highlighted 
with triangle head white arrows. Simple 
head white arrows indicate T cells and 
white arrowheads highlight ADRA1, 
ADRA2A, ADRB2, NPY and Y1R staining 
in cells other than T cells (positive control). 
Scale bar= 20 µm. 
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Figure 5. B cells in AL periprosthetic tissues and OA synovial membrane do not express TH, 
ADRA1, ADRA2A, ADRB2, NPY or Y1R  
The expression of TH, ADRB2, ADRA1 and ADRA2A (a), and the expression of NPY and Y1R (b) in B 
cells (CD20+) was evaluated in periprosthetic tissues from AL patients and in synovial tissues from OA 
patients through double immunohistochemistry staining. White arrows indicate B cells and white 
arrowheads highlight positive staining for TH, ADRA1, ADRA2A, ADRB2 and Y1R in cells other than B 
cells (positive control). Scale bar= 20 µm. 
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The absence of sympathetic innervation in periprosthetic tissues from AL 
patients is not mediated by the classic regulators of the innervation pattern.  
In a previous work (Vasconcelos et al. 2016, reference 21), using the same 
samples that were used in this study, we reported an unbalanced innervation 
pattern in hip periprosthetic tissues, mirrored by the lack of sympathetic 
nerve fibers. Here, in order to investigate the molecular mechanism 
underlying this effect, we evaluated the mRNA expression of the classical 
neurotrophins NGF and BDNF, of the nerve repellent molecule SEMA3A, 
and of the sympathetic nerve repellent factors SEMA3C and SEMA3F in the 
AL and OA joint tissues. No differences were found in the mRNA expression 
levels of NGF and BDNF between periprosthetic tissues and OA synovial 
membrane (Figure 6a). Interestingly, the mRNA levels of SEMA3A, SEMA3C 
and SEMA3F were found to be decreased in periprosthetic tissues when 
compared with OA synovial tissues (SEMA3A: p< 0.01; SEMA3C and 
SEMA3F: p< 0.05) (Figure 6b).  
 
Figure 6. Neurotrophins and semaphorins expression in AL periprosthetic tissues and OA 
synovial membrane. 
The mRNA levels of neurotrophins NGF and BDNF (a), and semaphorins SEMA3A, SEMA3C and 
SEMA3F (b) were assessed in OA synovial membrane and periprosthetic tissues from AL patients. 
Results are represented as mean ± SEM, for n=8-9 per group. ** p< 0.01, * p< 0.05.  
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Discussion 
In this study we show that the periprosthetic inflammatory response is not 
decoded by the sympathetic nervous system at systemic levels, but is 
mirrored locally in the hip joint by the impairment of adrenergic and NPY-
ergic signaling in macrophages. 
Pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 released by local 
immune cells were identified as key players in the central activation of 
sympathetic nervous system (14). Moreover, implant debris were shown to 
promote the in vitro release of pro-inflammatory cytokines by lymphocytes 
(25) and macrophages (26), and in OA an increase of TNF-α in synovial 
membrane and blood and of IL-6 in synovial fluid and blood was reported 
(27). In this study, the comparison of the IL-1β, IL-6 and TNF-α profile 
showed an increase in the serum levels of IL-6 in AL and OA patients (in 
comparison with healthy donors) but no differences between AL and OA. 
Such results highlight IL-6 as a main mediator of the systemic inflammatory 
response in the studied joint disorders. Still, these increased blood levels of 
IL-6 were not reflected in an increased systemic sympathetic tone neither in 
AL nor in OA patients, suggesting the absence of regulation of the 
inflammatory response by the systemic sympathetic signaling, even in 
scenarios in which debris are being released from implants. Moreover, the 
evaluation of the cortisol blood levels and the analysis of the cortisol/ serum 
IL-6 ratio, strong indicators of HPA axis activity (23), showed no significant 
differences between the three analyzed groups, suggesting no impact in the 
HPA axis activity.  
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The combined lack of activation of systemic sympathetic signaling and HPA 
axis supports the absence of a systemic control of the inflammatory reaction 
in both OA and AL conditions. 
Within the inflammation site, sympathetic nervous system can directly 
influence immune cells via the ADRs expressed on their cell surface (28). 
The sympathetic immunomodulatory effects are known to be dependent on 
parameters such as the ADRs profile and the catecholamines concentration. 
The stimulation of ADRA, sensitive to low concentrations of norepinephrine, 
are described to activate pro-inflammatory mechanisms, while the action on 
the ADRB2, sensitive to high concentrations of norepinephrine, activates 
anti-inflammatory mechanisms (14). The sympathetic influence on immune 
function can also be exerted by other neurotransmitters co-released with 
norepinephrine, such as NPY (15). In order to understand the impact of 
debris release in the local sympathetic control of the inflammatory response 
we investigated both the adrenergic and the NPY-ergic signaling in immune 
cells. In the follow up of our previous work (21), the expression of TH, 
ADRA1, ADRA2A and ADRB2 (adrenergic markers) and of NPY and Y1R 
(NPY-ergic markers) in macrophages, B and T cells, the main immune cell 
types which we have previously identify in AL periprosthetic tissues and in 
OA synovial membrane (21) were investigated by immunohistochemistry.  
Our immunostaining results showed that TH, ADRA1, ADRB2 and NPY were 
expressed by macrophages in OA synovial tissues but are absent in 
macrophages from periprosthetic tissues. These results show that both the 
adrenergic and the NPY-ergic arms are implicated in the local regulation of 
joint diseases inflammation by the sympathetic nervous system, indicating 
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that such local regulation is sensitive to debris released from orthopedic 
implants and reinforce macrophages as key cellular players in the process. 
Moreover, the absence of TH and ADRB2 in AL macrophages suggests a 
lack of sympathetic-mediated anti-inflammatory mechanisms in response to 
periprostetic inflammation. ADRA were found to be differentially expressed in 
OA and AL macrophages suggesting a debris-dependent activity of pro-
inflammatory mechanisms. In OA the pro-inflammatory activity was found to 
be mediated by both ADRA1 and ADRA2 while in AL only ADRA2 were 
found. 
We have previously shown that macrophages were more abundant in AL 
periprosthetic tissues than in OA synovial membrane, and that these cells 
had a distinct distribution in the two conditions: while macrophages in OA 
were confined to lining layer, in AL were found infiltrating the periprosthetic 
tissues (21). Still, the underlying biological meaning of such different 
macrophage amount and distribution in the local regulation of inflammation is 
not understood. An increased expression of pro-inflammatory M1 
macrophages was found in rheumatoid arthritis patients (29, 30) and in AL 
periprosthetic tissues when compared with OA synovial membrane (6). In 
vitro, IL-4 and IL-10 were shown to counteract M1 macrophages polarization 
induced by PMMA and UHMWPE implant particles, promoting macrophages 
polarization towards a M2 anti-inflammatory phenotype and inhibiting the 
inflammatory process (6-8, 31). In orthopedic implants the increased M1/M2 
ratio could be responsible for the perpetuation of inflammation, increasing 
osteolysis and eventually leading to implant failure. Still, very little is known 
regarding the underlying mechanisms of macrophage differential polarization 
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in the presence of implant wear debris. Previously, it was demonstrated that 
the stimulation of ADRB2 in macrophages promotes their differentiation 
towards an M2 anti-inflammatory profile and serves as a mean to prevent 
hyper-inflammation (24). In our study we observed that only OA 
macrophages, and not AL macrophages expressed ADRB2. Following, we 
decided to assess whether macrophages polarization in M1 or M2 could 
impact the ADRB2 expression profile. For this aim, an in vitro experiment 
exploring ADRB2 expression in M1 and M2 macrophages was performed. 
The results from this experiment showed that the expression of ADRB2 is 
lower in M1 pro-inflammatory phenotype macrophages than in M2, 
suggesting that the impairment of ADRB2 signaling observed in 
macrophages in AL tissues might be involved in the harshness of the 
periprosthetic inflammation.  
In regard to the NPY-ergic regulation, NPY produced by immune cells during 
inflammation is known to modulate the cellular activity through autocrine or 
paracrine actions (15, 32), and has been shown to decrease the expression 
of the pro-inflammatory TNF-α by macrophages after stimulation with LPS 
(33) and to increase the expression of the anti-inflammatory TGF-β1 (34), 
contributing to ameliorate the inflammatory response. Moreover, it was 
recently suggested that NPY promotes the differentiation of macrophages 
towards a M2 anti-inflammatory phenotype (35).  
Altogether, the observed lack of TH, ADRB2 and NPY expression in 
macrophages of AL periprosthetic tissues may input a preferential 
differentiation of macrophages towards a pro-inflammatory phenotype, 
increasing the M1/M2 ratio, which may underlie the perpetuation of 
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inflammation and an increased osteolysis leading to implant failure. Although 
several immunomodulatory roles of NPY were suggested to be achieved 
through Y1R (15), the expression of this receptor was not observed neither in 
macrophages in periprosthetic tissues nor in OA synovial membrane, 
suggesting the enrolment of other NPY receptors (namely Y2R and Y5R) in 
the NPY regulation of macrophages activity (32, 36). 
In regard to T cells, ADRA1 was found to be expressed by these cells in both 
OA and AL. This receptor has been described as an inhibitor of T cells 
proliferation (37). Considering the fact that our results show the expression of 
ADRA1 by mature T cells (CD3+) in both AL and OA tissues, a different 
putative role of ADRA1 in T cells-mediated inflammation, other than the 
inhibition of proliferation, which is independent of particles released by the 
implants is suggested. As observed in macrophages, T cells were found to 
express TH in OA but not in AL tissues, supporting the higher ability of non-
neuronal synthesis of catecholamines in OA synovial membrane when 
compared to AL periprosthetic tissues.  
Evidence showed a repulsion of sympathetic nerve fibers from inflamed 
tissues that cause the loss of anti-inflammatory neurotransmitters and allow 
the establishment of a privileged pro-inflammatory area (18, 38-40). In a 
previous work, performed in the same samples used in the present study, we 
have also reported the repulsion of sympathetic innervation from 
periprosthetic tissues in AL patient but not from synovial membrane in OA 
patients (21). 
Here, we investigate the putative involvement of well-studied neurotrophic 
factors, NGF and BDNF, of the nerve repellent molecule SEMA3A, and of 
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the sympathetic nerve repellent factors SEMA3C and SEMA3F in this 
specific innervation pattern. No differences were found in the expression 
levels of NGF and BDNF between AL periprosthetic tissues and OA synovial 
membrane, and the expression of the chemorepellent molecule SEMA3A, 
SEMA3C and SEMA3F was in fact lower in periprosthetic tissues as 
compared with OA synovial membrane. Such results indicate that the most 
well studied molecules involved in the modulation of the innervation pattern 
were not responsible for the repulsion of the sympathetic innervation from 
periprosthetic tissues of AL patients. Considering the fact that SEMA3A has 
also been described as having an immunomodulatory role (41-43), the 
observed decrease SEMA3A expression may be part of the mechanism 
underlying the different inflammatory profile between OA synovial membrane 
and periprosthetic tissues. In fact, decreased levels of SEMA3A were 
observed in synovial tissues from rheumatoid arthritis patients compared to 
synovial tissues in OA patients, and the reduction of SEMA3A expression 
was correlated with rheumatoid arthritis exacerbation (44). Moreover, 
overexpression of SEMA3A reduced inflammation in a mouse model of 
collagen-induced arthritis (45), further supporting SEMA3A as an important 
immunomodulatory molecule. 
Overall, in this work we show that periprosthetic inflammation in AL does not 
trigger a systemic response of the sympathetic nervous system but enforces 
the impairment of the local sympathetic signaling as a putative mean to 
enable the perpetuation of the inflammatory state. Macrophages were 
highlighted as key cellular players in the local regulation of inflammation by 
the sympathetic nervous system in a process that is implant wear debris-
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dependent and entails the reduction of both the adrenergic and the NPY-ergic 
signaling. The absence of TH, ADRB2 and NPY expression in macrophages 
in periprosthetic tissues from AL patients may underlie a preferential 
differentiation of macrophages towards a M1 pro-inflammatory phenotype, 
promoting inflammation and increased osteolysis that leads to implant failure. 
The local sympathetic signaling emerges, therefore, as a putative target to 
mitigate the inflammatory response to debris release and extending the 
lifespan of orthopedic implants. 
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Methods 
Samples 
Biological samples were collected from three groups of patients. Group 1 was 
constituted by twenty patients (20 hips) undergoing hip revision surgery due to 
AL, after exclusion of infection, recurrent dislocation and periprosthetic 
fractures. All patients had a metal-on-polyethylene coupling and eleven 
prosthesis were cemented. All acetabular components were revised and in 
five of those the femoral stem was also exchanged. In four patients metallosis 
was observed and the mean time to revision was 120.05±65.8 months. Group 
2 was constituted by fifteen patients (15 hips), submitted to primary hip 
replacement surgery for primary OA, after excluding patients with a known 
history of inflammatory or neoplastic diseases. Group 3 was constituted by 15 
healthy volunteers (i.e. without known osteoarticular or systemic diseases). 
Demographics from Groups 1-3 are presented in table 1. 
Serum was obtained from the blood collected, during the morning, previously 
to surgery in Groups 1 and 2, and in Group 3, and kept at -80ºC until 
analyses. Synovial tissue was removed during the surgical procedure in 
Group 2 patients, and periprosthetic tissue was collected in Group 1.  
This study was approved by the Ethics Committee of Centro Hospitalar São 
João and all patients signed an informed consent to the use of their samples 
for research purposes. All the procedures were in accordance with the 
Helsinki Declaration of 1975, as revised in 2000. 
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 N Age (years) Gender Mean (±SD) p N of male/female p 
Group 1 
Revision Surgery due to AL 20 70.35 ± 11.4 
0.119 
6/14 
0.537 Group 2  
Primary Surgery due to OA 15 63.33 ± 14.5 6/9 
Group 3 
Healthy Donors 15 32.87 ± 3.4 <0.001* 9/6  
Table 1. Demographic data on included patients 
AL- Aseptic loosening; OA- Osteoarthritis. *Comparing Group 3 with both Group 1 and Group 2. 
 
ELISA 
The levels of Epinephrine/Norepinephrine, NPY and Cortisol were measured 
in the serum obtained from AL patients, OA patients and healthy donors, 
using ELISA kits from Abcam plc (Cambridge, UK; catalog number: 
AB108665), Merck KGaA (Darmstadt, Germany; catalog number: EZHNPY-
25K) and Abnova (Taoyuan, Taiwan; catalog number: KA1877) respectively, 
according to the manufacturers’ protocols. The serum levels of interleukin (IL)-
1β, IL-6 and Tumor necrosis factor alpha (TNF-α) were also measured in the 
same groups, using ELISA kits from BioLegend (CA, USA; Catalog number: 
430507). 
 
Monocyte isolation and macrophage differentiation  
Human monocytes were isolated from healthy blood donors and differentiated 
into macrophages (46). Briefly, 106 monocytes/mL/3,8cm2 were cultured for 
10 days in RPMI1640 medium, supplemented with 10% Fetal bovine serum 
(FBS) and 100 U/mL penicillin and 100 µg/mL streptomycin, in the absence of 
Macrophages colony-stimulating factor (M-CSF) or other exogenous factors. 
10 ng/mL LPS (Sigma-Aldrich) or IL-10 (ImmunoTools, Friesoythe, Germany) 
were added, for additional 72h, to polarize macrophages towards M1 or M2 
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phenotype, respectively. Unstimulated macrophages (M0) were maintained 
with renewed medium.  
 
Double immunofluorescence staining 
The expression of markers of the sympathetic nervous system by immune 
cells (macrophages, B cells and T cells) was evaluated through a double 
immunofluorescence staining analysis. The collected tissues were 
formaldehyde-fixed and processed for paraffin embedding, and cross-sections 
of 3 µm thickness were cut in the microtome (RM2255, Leica Biosystems). 
Deparaffinized and dehydrated sections were placed in antigen retrieval for 20 
min at 97ºC (10 mM citrate buffer, pH 6.0). After quenching endogenous 
fluorescence with 0.1% NaBH4 and 100 mM NH4Cl, sections were incubated 
with blocking buffer (10% FBS, 1% Bovine serum albumin (BSA), 0.2% Triton 
X-100). 
Simultaneous incubation of each primary antibody against immune cells 
(antibodies mouse anti-CD68 (clone 514H12, dilution 1:100, Novocastra, UK), 
anti-CD20 (clone L26, dilution 1:100, Cell Marque, USA), anti-CD3 (clone 
PS1, dilution 1:100, Biocare Medical, USA)) with each primary antibody 
against sympathetic markers (antibodies rabbit anti-TH (dilution 1:100, Merck 
KGaA, Darmstadt, Germany), anti-ADRA1 (dilution 1:100, Abcam, USA), anti-
ADRA2A (dilution 1:200, Abcam, USA), anti-ADRB2 (dilution 1:100, 
Proteintech, USA), anti-NPY (dilution 1:1000, Sigma-Aldrich, USA) or anti-
Y1R (dilution 1:500, Immunostar, USA)) were performed overnight at 4ºC. 
For signal detection, tissue sections were incubated for 1 hour at room 
temperature (RT) with a mixture of anti-rabbit Alexa Fluor 568 antibody and 
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anti-mouse Alexa Fluor 488 antibody (1:1000 dilution, Life Technologies, 
USA), incubated with DAPI and then mounted with Fluoroshield Mounting 
Medium (Abcam, USA). Immunostaining images were acquired on the 
confocal Leica TCS SP2 AOBS (Leica Microsystems, Germany) and Leica 
TCS SP5 microscope (Leica Microsystems, Germany).  
 
Gene expression analysis 
Synovial tissues were homogenized in liquid nitrogen using a mortar and 
pestle to preserve RNA integrity. RNA from synovial tissues and from 
macrophages was extracted and purified using TRIzol (Invitrogen, UK) and 
Direct-zol™ RNA MiniPrep (ZYMO Research, USA), according to the 
manufacturers’ instructions.  
RNA purity was estimated from the ratio of absorbance readings at 260 and 
280 nm and only ratio between 1.8 and 2 were accepted. RNA quality was 
verified in agarose gel and RNA concentration was determined in a NanoDrop 
spectrophotometer (NanoDrop™ 1000 Spectrophotometer, Thermo Fisher 
Scientific, Wilmington, Delaware, USA NanoDrop). RNA was reverse 
transcribed using the SuperScriptTM First-Strand Synthesis System for reverse 
transcription-polymerase chain reaction (RT-PCR) (Invitrogen, Carlsbad, CA, 
USA).  
The transcriptional levels of ADRA1A, ADRA1B, ADRA1D, ADRA2A and 
ADRB2 in macrophages and neurotrophins (Nerve growth factor (NGF) and 
Brain-derived neurotrophic factor (BDNF)) and semaphorins (SEMA3A, 
SEMA3C and SEMA3F) in the AL and OA tissues were evaluated by 
quantitative real time PCR (qRT-PCR) in the CFX96 Touch Detection System 
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(Bio-rad, USA). β2 microglobulin (B2M) was used as reference gene for 
internal normalization. The primers used were as follows: ADRA1A sense 
primer: 5’-TCAT 
GTACTGCCGCGTCTAC-3’; ADRA1A antisense primer: 5’-
GGGCGTTTTTCCGATGG 
ATG-3’; ADRA1B sense primer: 5’-CTCTACCGCTTGGCTCCTTGT-3’; 
ADRA1B antisense primer: 5’-GGAGCATGGGTAGATGATGGG-3’; ADRA1D 
sense primer: 5’-TCT 
CCCGTGAGAAGAAAGCG-3’; ADRA1D antisense primer: 5’-
CGGGAACAAGGAGCCG 
AG-3’; ADRA2A sense primer: 5’-ATCCTGGCCTTGGGAGAGAT-3’; ADRA2A 
antisense primer: 5’-TCTCAAAGCAGGTCCGTGTC-3’; ADRB2 sense primer: 
5’GGACTTCCATTG 
ATGTGCTGT -3’; ADRB2 antisense primer: 5’-
GTCAGCAGGCTCTGGTACTTG-3’; NGF sense primer: 5’-
AGCGCAGCGAGTTTTGG-3’; NGF antisense primer: 5’-GCTGCTCCCT 
TGGTAAACTG-3’; BDNF sense primer: 5’- GATGCTCAGTAGTCAAGTGCC-
3’; BDNF antisense primer: 5’-GCCGTTACCCACTCACTAATAC-3’; SEMA3A 
sense primer: 5’CAG 
CCATGTACAACCCAGTG-3’; SEMA3A antisense primer: 5’-
ACGGTTCCAACATCTGT 
TCC-3’; SEMA3C sense primer: 5’-ATCCGGTCCTGATCTTCATC-3’; 
SEMA3C antisense primer: 5’-CAGCCCCAAGCAAGAGTTTA-3’; SEMA3F 
sense primer: 5’-CCAACTACCA 
GTGGATGCCC-3’; SEMA3F antisense primer: 5’-
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GTACACGGCCTGGTACATGA-3’; B2M sense primer: 5’-
CCAGCGTACTCCAAAGATTCAG-3’; B2M antisense primer: 5’- 
AGTCAACTTCAATGTCGGATGG-3’. Relative transcription levels were 
calculated by comparative threshold cycle quantification (ΔCt method) using 
B2M as reference gene. 
 
Statistical analyses 
All data were assessed for normal distribution and non-parametric analyses 
were performed whenever normal distribution was not followed. Hormones 
and IL-6 levels, and the cortisol/IL-6 ratio were analyzed by Kruskal-Wallis 
test followed by Dunn’s multiple comparison test. mRNA expression of 
neutrophins and semaphorins in the synovial tissues was analyzed by Mann-
Whitney test and ADRs mRNA expression in macrophages by the Repeated 
Measures ANOVA followed by Holm-Sidak’s multiple comparisons test. 
Differences were considered at the significant level of p<0.05. All data are 
expressed as mean ± SEM. Statistical analyses were performed using the 
software Prism 6, GraphPad software, San Diego, CA, USA). 
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Biological events leading to hip osteoarthritis and aseptic loosening are yet to 
be fully detailed, with our intervention and management of both primary hip 
osteoarthritis (HOA) and failed total hip arthroplasty (THA) remaining 
reactionary and palliative. Most of our medical intervention happens when 
there are established radiographic changes. At this time significant damage 
has occurred both at joint level in primary cases and at the bone stock in 
failed THA (1, 2). 
Inflammation is common to osteoarthritis (OA) and aseptic loosening (3, 4). 
HOA is characterized by inflammatory and immune cell infiltration and 
cytokine secretion (4, 5), that leads to a vicious circle of cartilage degradation 
and chronic inflammation (6). After THA, inflammation is a response to 
released wear debris and particles from the implants, which can initiate 
important immunological reactions, that eventually cause implant failure (7) 
Over the past years, accumulated evidence has clearly attributed a pivotal 
role to the sympathetic nervous system and its neurotransmitters in the 
regulation of chronic inflammatory conditions (8, 9). Current literature reports 
on the relationship between innervation and inflammation in osteoarthritic 
synovial tissues (10), but the influence of the neuroimmune axis in biological 
events leading to aseptic loosening has been poorly explored (11).  
In this context, there is a growing interest in understanding the biological 
response to both HOA and failure of THA so that new therapeutic strategies 
can be developed.  
In chapter II we performed the first systematic review on neuroimmune 
expression in HOA patients using data from studies in humans (12). This 
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study allows an integrated approach of the changes caused by HOA, both at a 
local and systemic level, contrary to most available studies that focus solely 
on the actions of a small number of molecules in a specific environment 
(bone, cartilage, synovial tissue).  
A deregulation in the balance between pro-inflammatory and anti-
inflammatory cytokines was reported. Interleukin (IL)-6 and tumor necrosis 
factor (TNF)-α were found to be significantly increased both locally and 
systemically (12). These increases have been described previously in patients 
with HOA, as well as their pro-inflammatory and cartilage degradation effects 
(13, 14). IL-10, a known anti-inflammatory cytokine, is decreased at a 
systemic level, compatible with a pro-inflammatory state in HOA, but 
increased locally, which is interpreted as a local attempt to control the 
inflammatory process (15). Transforming growth factor (TGF)-β was also 
increased at a local level in HOA patients, but no systemic differences could 
be found.  
In what concerns the influence of the neuroimmune axis in biological events 
leading to HOA, only two articles were found regarding neuropeptides 
expression in HOA comparing with healthy subjects (16, 17), which is 
representative of the lack of available information in this area. Nerve fibers 
and increased levels of both calcitonin gene-related peptide (CGRP) and 
substance P (SP) were found in the OA synovial membrane when compared 
to normal subjects (16, 17), mostly in a perivascular location, a fact also found 
in papers studying the influence of nerve fibers and neuropetides in bone 
metabolism (18). Both SP and CGRP are known to play a significant role in 
pain, as well as contributing to the inflammatory process and cartilage 
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degradation in both HOA and inflammatory diseases as rheumatoid arthritis 
(RA) (19, 20). SP was reported to play a pro-inflammatory and catabolic role 
in the development of OA (21), by increasing the concentrations of IL-1, IL-6 
and TNF (22), while CGRP and sympathetic neurotransmitters present an anti 
inflammatory role by inhibiting these cytokines actions (23, 24). These 
findings are in accordance with previous works stating the importance of 
these neuropeptides in the modulation and regulation of the inflammatory 
process in OA (25, 26). Despite the alterations described above, our review 
highlights the lack of a clear analytical profile of HOA, both locally and 
systemically. In addition, our understanding of the influence of the 
neuroimmune axis in the response to implantable materials, and its influence 
in the biological processes leading to its failure is still very limited.  
In chapter III we addressed the local inflammatory response and 
neuroimmune profile of aseptic loosening patients and compared it with 
patients with clinical end stage HOA. This was the first study performing this 
analysis in the hip of human patients, and brought a new insight into the role 
of the neuroimmune axis in the hip of HOA and aseptic loosening patients. To 
our knowledge, only two articles had previously addressed the local 
innervation profile of patients with aseptic loosening, and presented 
contradictory results (27, 28). Our results demonstrated different immune 
responses, with macrophage presence being more intense, and distribution 
more dispersed in aseptic loosening compared with HOA patients. 
Macrophages presence is a response to the presence of wear particles (29, 
30), and promotes the expression of inflammatory cytokines that can lead to 
osteolysis (31).  
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Regarding the inflammatory profile no differences were found in pro-
inflammatory cytokines between the two groups. IL-10 was locally increased 
in both groups, with a tendency to a significant increase in the aseptic 
loosening group. A similar finding was reported when comparing HOA with 
healthy patients in our systematic review. The same interpretation, regarding 
a local attempt to control the inflammation in aseptic loosening patients can 
be made, a feature also described by other authors (32). 
TGF-β was significantly increased in synovial messenger ribonucleic acid 
(mRNA) in OA patients when compared to aseptic loosening, but with 
increased immunostaining in aseptic loosening when compared to OA. The 
effects of TGF-β in inflammatory processes are not clear. It can present a 
dual effect on arthritic diseases and an action dependent on the local existing 
context (33). TGF-β can contribute to matrix production and chondrocyte 
proliferation at a local level (34), but also induce pro-inflammatory cytokine 
expression (35). There is an increased interest regarding its potential 
therapeutic effects as an immunomodulator (33). Locally this was the main 
difference found, that led us to investigate if there was any systemic alteration 
in TGF expression, which was not confirmed. These findings are in 
accordance with what was reported in our systematic review, where a local 
increase of TGF, without systematic translation, was also described when 
comparing HOA with healthy patients (12). 
Interestingly, our finding results revealed that HOA patients have distinct local 
innervation when compared to aseptic loosening patients. Both HOA and 
aseptic loosening patients present sensory innervation with positive SP and 
CGRP fibers, but with a different distribution. While in OA patients their 
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presence is localized and close to blood vessels, in aseptic loosening its 
distribution is dispersed. We also reported an absence of sympathetic nerve 
fibers in aseptic loosening tissues when compared to OA, which is a distinct 
feature in the innervation profile of this group, and the first time this was 
described. This finding is similar to what is found in RA patients (36), and 
could, simultaneously, be related to the presence of a persistent inflammatory 
environment, and a cause associated with its maintenance. Current evidence 
gives the sympathetic nervous system and its neurotransmitters a pivotal role 
in the regulation of chronic inflammatory conditions (8, 9), with activation of 
the sympathetic nervous system in the context of inflammation resulting in the 
release of high amounts of sympathetic neurotransmitters, like norepinephrine 
(NE) and neuropeptide Y (NPY), known to induce anti-inflammatory effects 
(24).  
These insights shed light on neuro-immune interplay in both aseptic loosening 
and HOA and underline the need to better understand this crosstalk to unravel 
potential mechanisms for targeted-therapies to improve hip joint lifetime and 
treatment. 
In chapter IV we investigated further whether in aseptic loosening joint occurs 
a complete shutdown of the sympathetic activity without rescue mechanisms, 
and if the observed alterations are also reflected at systemic level. 
Additionally, putative local mechanisms underlying the lack of sympathetic 
innervation were also explored.  
Locally we confirmed that the usual effectors for the sympathetic anti-
inflammatory action (37, 38), β2-adrenergic receptors (β2-ARs) and NPY, 
were absent in macrophages in aseptic loosening patients but present in the 
Concluding	Remarks	and	Future	Perspectives	
	 188	
OA group. Macrophages were described in chapter III as being the most 
prevalent immune cell found in local tissues of both THA and AL patients. β2-
ARs and NPY-Y1 receptors are known to stimulate M2 macrophages that 
have a pro-regenerative and anti-inflammatory action when compared to M1 
(39, 40). Y1 when activated by NPY also reduces the expression of pro-
inflammatory cytokine TNF-α  by macrophages (41) and increases the 
expression of TGF-β (42). The observed lack of β2-ARs and NPY expression 
in macrophages of aseptic loosening periprosthetic tissues may input a 
preferential differentiation of macrophages towards a pro-inflammatory 
phenotype, increasing the M1/M2 ratio, which may underlie the perpetuation 
of inflammation and increased osteolysis leading to implant failure. Together 
all these findings are in favor to local reduction of the anti-inflammatory effects 
performed by the sympathetic system, and the perpetuation of a pro-
inflammatory environment in aseptic loosening patients.  
Concerning the impact on the systemic sympathetic nervous system activity, 
there was no difference in the expression of epinephrine, NE and NPY 
between OA, aseptic loosening and healthy groups. As expected, when 
comparing the systemic expression of pro-inflammatory cytokines, there was 
an increase in the OA and aseptic loosening groups versus healthy patients, 
but no difference between the OA and aseptic loosening groups. These 
results confirm the local findings in chapter III regarding no differences 
between groups in local cytokine expression, and fail to demonstrate any 
systemic consequence of the sympathetic differences seen between the OA 
and aseptic loosening groups. Also we found no systemic differences in 
cortisol expression or cortisol/IL6 ratio between groups, which means no 
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impact in the Hypothalamus-Pituitary-Adrenal (HPA) axis activity. As pointed 
out in chapter IV, the HPA axis is a system which together with sympathetic 
nervous system, compose the hormonal pathway through which the central 
nervous system exerts a regulatory control over inflammation (43). 
This lack of systemic impact in the regulation of the sympathetic nervous 
system, leads us to agree with authors who believe that in humans the 
pathological responses occurring at the hip seem to be mostly confined to the 
joint (44). 
The study of these processes in humans is important to overcome the fact 
that most available studies translate data from in vitro or in vivo animal 
models and compare them to the human situation (45).  
In chapter III and IV we used data from analyses of tissues from late HOA or 
failed THA. Tissues retrieved during surgery represent late stages of a 
process that, in the majority of cases, reflects a long lag period from the time 
at which the local homeostasis was first disrupted (3). This contributed to 
enlighten the changes of end stage HOA and aseptic loosening, describing 
features and differences that were previously unknown, but did not allow the 
evaluation of local findings during the development or earlier stages of these 
diseases. 
Another important reflection regards the individual methods found in available 
works, and their implication in our current knowledge and ability to make 
assumptions.  
In our systematic review there are limitations in sample sizes, with most 
articles using very few patients. The population used as controls is poorly 
defined and cannot assure that the comparisons made are not impacted by 
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these facts (46, 47). The methods for sample collection, processing and 
analysis are also heterogeneous. For the same reasons a quantitative 
analysis was not possible. Future studies should focus in better-defined 
criteria for patient and control selection, sample collection, processing and 
analysis.  
In our experimental works, the sample numbers are similar to the average 
numbers published in this field (32), and were collected by the same team to 
minimize selection bias. We recognize that the interpretation of the variability 
described between groups can be influenced by the biological response to 
other systemic conditions, which we were not able to eliminate in patients 
selection. The use of samples from OA patients allows to overcome the lack 
of access to healthy synovial tissue or well-integrated implants. However, the 
use of OA tissues as control is a limitation of the majority of studies because 
two different immune responses are being compared in a pathological 
context. Future studies must include more defined populations and apply 
more strict inclusion criteria, regarding the presence of relevant comorbidities 
with impact on the immune system. An increase in the number of patients 
treated arthroscopically for non-degenerative conditions of the hip may also 
allow the collection of healthy samples from synovial membrane, cartilage and 
bone, and overcome some of the limitations described. 
Interventions that would be disease modifying in HOA are elusive for the time 
being, and joint arthroplasty despite highly successful in relieving symptoms, 
is not a procedure without significant risks and cost. Future studies should 
continue to enlighten HOA and aseptic loosening pathophysiology, as the 
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potential for improved management of HOA and THA failure relies in shifting 
the treatment paradigm to the earliest stages of the condition’s pathogenesis. 
Overall, under the scope of this thesis, we described a new pattern of 
innervation in AL, characterized by the absence of sympathetic activity. This 
impairment occurs locally at the hip, affecting both adrenergic and NPYergic 
signaling, without systemic translation. This finding highlights the local 
sympathetic signaling as a putative target to mitigate the inflammatory 
response to debris release and consequently extending the lifespan of 
orthopedic implants. 
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